UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-CSR CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act file number 811-10325 VANECK VECTORS ETF TRUST (Exact name of registrant as specified in charter) 666 Third Avenue, New York, NY 10017 (Address of principal executive offices) (Zip code) Van Eck Associates Corporation 666 Third Avenue, New York, NY 10017 (Name and address of agent for service) Registrant's telephone number, including area code: (212) 293-2000 Date of fiscal year end: SEPTEMBER 30 Date of reporting period: MARCH 31, 2018
ITEM 1. REPORT TO SHAREHOLDERS
SEMI-ANNUAL REPORT March 31, 2018 (unaudited)
|
VANECK VECTORS® | |
Biotech ETF | BBH |
Environmental Services ETF | EVX® |
Gaming ETF | BJK® |
Generic Drugs ETF | GNRX |
Pharmaceutical ETF | PPH® |
Retail ETF | RTH® |
Semiconductor ETF | SMH® |
800.826.2333 | vaneck.com |
The information contained in the management discussion represents the opinions of VanEck Vectors ETFs and may differ from other persons. This information is not intended to be a forecast of future events, a guarantee of future results or investment advice. The information contained herein regarding each index has been provided by the relevant index provider. Also, unless otherwise specifically noted, any discussion of the Funds’ holdings and the Funds’ performance, and the views of VanEck Vectors ETFs are as of March 31, 2018, and are subject to change.
March 31, 2018 (unaudited)
Dear Shareholder:
We are pleased to present this semi-annual report for the seven industry exchange-traded funds (ETFs) of the VanEck Vectors® ETF Trust for the six-month period ended March 31, 2018.
One of the two top performing funds in our suite of industry ETFs was the VanEck Vectors Semiconductor ETF (NYSE Arca: SMH) which returned 13.36% for the period under review.
The semiconductor industry ended 2017 on a high: global sales for 2017 of $412.2 billion were 21.6% higher than those in 2016. In addition, sales for December 2017 ($38.0 billion) and the fourth quarter 2017 ($114.0 billion) were the highest monthly and quarterly sales respectively ever recorded.1 According to John Neuffer, president and CEO of the Semiconductor Industry Association, “[a]s semiconductors have become more heavily embedded in an ever-increasing number of products—from cars to coffee makers—and nascent technologies like artificial intelligence, virtual reality, and the Internet of Things have emerged, global demand for semiconductors has increased, leading to landmark sales in 2017 and a bright outlook for the long term.”2
The industry started 2018 on a solid footing. In January, sales were up 22.7% compared to January 2017 and the market grew year over year for the eighteenth consecutive month.3 Sales in February were also solid, up 21% compared to February 2017. Fourth quarter earnings from several of the large chipmakers, reported in the first quarter of 2017,4 were particularly solid, with the vast majority of reporting companies in SMH portfolio beating earnings expectations.
Semiconductors – Worldwide Market Billings: 3-Month Moving Averages ($bn)
Source: Semiconductor Industry Association. Data as of January 31, 2018. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue. Past performance is no guarantee of future results; current performance may be lower or higher than the performance data quoted.
Access investment and market insights from VanEck’s investment professionals by subscribing to our blogs. To subscribe to the updates, please contact us at 800.826.2333 or visit vaneck.com/subscription to register.
1 |
VANECK VECTORS ETFs
(unaudited) (continued)
Thank you for participating in the VanEck Vectors ETF Trust. On the following pages, you will find the performance record of each of the funds for the six months ended March 31, 2018. You will also find their financial statements. We value your continuing confidence in us and look forward to helping you meet your investment goals in future.
Jan F. van Eck
Trustee and President
VanEck Vectors ETF Trust
April 16, 2018
Represents the opinions of the investment adviser. Past performance is no guarantee of future results. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.
1 | Semiconductor Industry Association: Annual Semiconductor Sales Increase 21.6 Percent, Top $400 Billion for First Time, https://www.semiconductors.org/news/2018/02/05/global_sales_report_2017/annual_semiconductor_sales_increase_21.6_percent_top_ 400_billion_for_first_time/ |
2 | Ibid. |
3 | Semiconductor Industry Association: January Semiconductor Sales Up 22.7 Percent Compared to Last Year, https://www.semiconductors.org/news/2018/03/05/global_sales_report_2017/january_semiconductor_sales_up_22.7_percent_compared_ to_last_year/ |
4 | Semiconductor Industry Association: Global Semiconductor Sales Up 21 Percent Year-to-Year in February, https://www.semiconductors.org/news/2018/04/02/global_sales_report_2017/global_semiconductor_sales_up_21_percent_year_to_year_ in_february/ |
2 |
Management Discussion (unaudited)
Four of the seven VanEck Vectors Industry ETFs realized positive performance in the six months ended March 31, 2018. The two best performers were VanEck Vectors Retail ETF (NYSE Arca: RTH), posting a total return of 16.26%, and VanEck Vectors Semiconductor ETF (NYSE Arca: SMH), in second place, providing a total return of 13.36%.
Source: VanEck. Returns based on NAV. The performance data quoted represent past performance. Past performance is not a guarantee of future results. Performance information for the Funds reflects temporary waivers of expenses and/or fees. Had the Funds incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Funds will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than performance data quoted.
Biotech – Not helped by State of the Union address
Biotech stocks failed to perform well over the six-month period. Following highs through mid-October, biotech stocks subsequently fell over the next three months to end 2017 down on the quarter. Despite some recovery through the end of January, stocks were not helped by President Trump’s mention of “fixing the injustice” of the high prices of U.S. drugs in his State of the Union address,1 nor the announcement of a prospective joint health care venture between Amazon.com, Berkshire Hathaway, and JPMorgan Chase & Co.2 The selloff at the end of the month and into the first week of February saw biotech stocks plummet. The recovery thereafter through the end of the reporting period on March 31, 2018 was minimal.
Positive contributions to the Fund’s performance came mainly from three companies: Illumina, Neurocrine Biosciences, and Vertex Pharmaceuticals (4.6%, 2.0%, and 5.0% of Fund net assets respectively†). The companies that detracted most from performance were Celgene, Incyte, and Regeneron Pharmaceuticals (7.3%, 4.2%, and 4.8% of Fund net assets, respectively†).
Environmental Services – No lasting benefit in 2018 from 2017 hurricanes
Following the steep improvement in their performance in both August and September 2017 (on the back of the three hurricanes that had hit the U.S. and its territories in the Caribbean), environmental services stocks essentially moved sideways thereafter, with a number of ups and downs, ending the six-month period under review down slightly.
While large- and small-cap stocks provided positive total returns, their contribution was outweighed by the negative total returns of the Fund’s mid-cap companies. Waste Management (10.0% of Fund net assets†), Cantel Medical (3.9% of Fund net assets†), and STERIS (10.2% of Fund net assets†) were the top three contributors to positive total returns. CECO Environmental (1.9% of Fund net assets†), Stericycle (3.8% of Fund net assets†), and ABM Industries (3.9% of Fund net assets†) detracted the most from performance.
3 |
VANECK VECTORS ETFs
(unaudited) (continued)
The Fund posted a rise of 10.89% for the six-month period. The fourth quarter of 2017 was strong with gaming stocks on an upward trajectory through the end of the year. In Macau, China—the world’s biggest gaming hub—the improvement in the gaming industry’s fortunes over the final three months of 2017 was impressive. In each of these months the gross revenue from “Games of Fortune” (as the Macau authorities3 describe them) was higher than that recorded in the same month in the prior year. In October, November, and December 2017, they were 22.1%, 22.6%, and 14.6%, respectively, higher than in the same months in 2016.4 2018 started strongly, with revenues in January, February, and March up 36.4%, 5.7%, and 22.2%, respectively, over 2017.5 In Nevada, the narrative for the last quarter of 2017 and the start of 2018 was not as rosy. While the “gaming wins” in both October and December may have increased incrementally year over year, the “gaming win” for November decreased 2.3% compared with that in November 2016.6 While February 2018’s win may have been 7.68% up on that of February 2017, January’s was 2.05% down on that of January 2017.7
U.S. listed companies were the leading contributors to performance, followed by those listed in China (Hong Kong). The other major contributors were companies in Australia and the U.K. Only Swedish gaming businesses detracted from the Fund’s overall positive performance.
Generic Drugs – Still a tough, but positive, environment
The Fund had a good six months, ending the period up 10.78%. Following steady gains through the fourth quarter 2017, generic drugs stocks (perhaps somewhat surprisingly) also faced a significant sell-off in early February 2018 from which they failed to recover fully by the end of the six-month reporting period. But they still remained up over the full period under review.
The biotechnology and pharmaceuticals sectors contributed the most to the Fund’s performance. The majority of negative performance was provided by the chemicals sector. In terms of individual companies, South Korean company Celltrion (8.0% of Fund net assets†) was the single largest contributor to performance. U.S. company Albemarle (3.0% of Fund net assets†) was the single largest detractor from performance.
Pharmaceutical – Not helped by State of the Union address
Pharmaceutical stocks had a lackluster six months. However, unlike biotech stocks, they ended the period down only 1.24%. Having hit a high for the period toward the end of January, pharma stocks plummeted in the selloff thereafter, hitting a low in early-February and slumping thereafter further, if fitfully, through to the end of March. Along with biotech stocks, they, too, were not helped by the mention of drugs prices in President Trump’s State of the Union address.
While Mylan and Zoetis (4.4% and 4.7% of Fund net assets, respectively†) were the two largest positive contributors to performance, Mallinckrodt and Sanofi (0.7% and 5.1% of Fund net assets, respectively†) were the Fund’s two largest detractors.
Retail – eCommerce remains solid
The Fund returned a very healthy 16.26% for the six-month period under review. Retail sales (excluding automobiles, gasoline stations, and restaurants) in the U.S. over the last three months of 2017 proved to be robust. Following retail sales up 4.3% in October,8 in November and December, sales increased 5.5% over 2016 to reach $691.9 billion.9 This included some $138.4 billion in online and other non-store sales, up 11.5% over 2016.10 These sales results beat the National Retail Federation forecast of approximately between $678 billion and $682 billion. The 5.5% was the largest increase since that of 5.2% seen in 2010.11 2018 started strongly with retail sales (excluding automobiles, gasoline stations, and restaurants) in January, up 5.4% on 2017.12 Although growth in February was a little slower, 4.4% year over year and 0.3% (seasonally adjusted) up in January,13 according to National Retail Federation Chief Economist Jack Kleinhenz: “With consumer confidence and employment growing, economic fundamentals are favorable for spending to expand in the coming months.”14
While stores involved in Internet and catalog retailing, in particular Amazon.com (19.3% of Fund net assets†), contributed by far the most to the positive performance of the Fund, both specialty and multiline retailers also made useful contributions to performance. Health care providers and services companies detracted from performance.
4 |
Semiconductor – Industry sales continue to boom
The Fund returned 13.36% for the six-month period under review. Global sales for 2017 of $412.2 billion were 21.6% higher than those in 2016. In addition, sales for December 2017 ($38.0 billion) and the fourth quarter 2017 ($114.0 billion) were the highest monthly and quarterly sales respectively ever recorded.15 Thereafter semiconductor sales in the first two months of 2018 also remained strong. In January, sales were up 22.7% compared to January 2017 and the market grew year over year for the eighteenth consecutive month.16 While in February, sales growth was a little down from January, they were still up 21% compared to February 2017.17
Large-capitalization stocks continued to be key drivers of SMH’s returns. Intel, Taiwan Semiconductor Manufacturing, and NVIDIA (8.1%, 7.8% and 5.1% of Fund net assets, respectively†) were the three best performing companies. Advanced Micro Devices, Cadence Design, and Broadcom (2.4%, 2.2%, and 5.0% of Fund net assets, respectively†) detracted most from the Fund’s performance.
† | All Fund assets referenced are Total Net Assets as of March 31, 2018. |
1 | CNN Money: Trump wants to fix ‘injustice’ of high drug prices. But can he?, http://money.cnn.com/2018/01/31/investing/trump-state-of-the-union-drug-prices/index.html |
2 | U.S. News: Health Stocks Pressured Under JPM-AMZN-BRK Venture, https://money.usnews.com/investing/stock-market-news/articles/2018-01-31/health-care-stocks-jpm-amzn-brk |
3 | Gaming Inspection and Coordination Bureau, Macao SAR: Monthly Gross Revenue from Games of Fortune, http://www.dicj.gov.mo/web/en/information/DadosEstat_mensal/2017/index.html |
4 | Ibid. |
5 | Gaming Inspection and Coordination Bureau, Macao SAR: Monthly Gross Revenue from Games of Fortune, http://www.dicj.gov.mo/web/en/information/DadosEstat_mensal/2018/index.html |
6 | Nevada Gaming Control Board: Abbreviated Revenue Release, http://gaming.nv.gov/index.aspx?page=172 |
7 | Ibid. |
8 | National Retail Federation: October Retail Sales Up 4.3 Percent Over Last Year, https://nrf.com/media/press-releases/october-retail-sales-43-percent-over-last-year |
9 | National Retail Federation: Holiday Retail Sales Increased 5.5 Percent in 2017, Exceeding NRF Forecasts and Showing Strongest Gain Since Great Recession, https://nrf.com/media/press-releases/holiday-retail-sales-increased-55-percent-2017-exceeding-nrf-forecast-and |
10 | Ibid. |
11 | Ibid. |
12 | National Retail Federation: January Retail Sales Continue Strong After Holidays, Up 5.4 Percent Over Last Year, https://nrf.com/media/press-releases/january-retail-sales-continue-strong-after-holidays-54-percent-over-last-year |
13 | National Retail Federation: February Retail Sales Increase 4.4 Percent Over Last Year, https://nrf.com/media/press-releases/february-retail-sales-increase-44-percent-over-last-year |
14 | Ibid. |
15 | Semiconductor Industry Association: Annual Semiconductor Sales Increase 21.6 Percent, Top $400 Billion for First Time, https://www.semiconductors.org/news/2018/02/05/global_sales_report_2017/annual_semiconductor_sales_increase_21.6_percent_top_40 0_billion_for_first_time/ |
16 | Semiconductor Industry Association: January Semiconductor Sales Up 22.7 Percent Compared to Last Year, https://www.semiconductors.org/news/2018/03/05/global_sales_report_2017/january_semiconductor_sales_up_22.7_percent_compared_ to_last_year/ |
17 | Semiconductor Industry Association: Global Semiconductor Sales Up 21 Percent Year-to-Year in February, https://www.semiconductors.org/news/2018/04/02/global_sales_report_2017/global_semiconductor_sales_up_21_percent_year_to_year_in _february/ |
5 |
VANECK VECTORS ETF TRUST
(unaudited)
Hypothetical $1,000 investment at beginning of period
As a shareholder of a Fund, you incur operating expenses, including management fees and other Fund expenses. This disclosure is intended to help you understand the ongoing costs (in dollars) of investing in your Fund and to compare these costs with the ongoing costs of investing in other mutual funds.
The disclosure is based on an investment of $1,000 invested at the beginning of the period and held for the entire period, October 1, 2017 to March 31, 2018.
Actual Expenses
The first line in the table below provides information about account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period.”
Hypothetical Example for Comparison Purposes
The second line in the table below provides information about hypothetical account values and hypothetical expenses based on the Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.
Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.
Beginning Account Value October 1, 2017 | Ending Account Value March 31, 2018 | Annualized Expense Ratio During Period | Expenses Paid During the Period* October 1, 2017 - March 31, 2018 | |||||||||||||
Biotech ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 901.40 | 0.35 | % | $1.66 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,023.19 | 0.35 | % | $1.77 | |||||||||
Environmental Services ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 995.50 | 0.56 | % | $2.79 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,022.14 | 0.56 | % | $2.82 | |||||||||
Gaming ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,108.90 | 0.65 | % | $3.42 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,021.69 | 0.65 | % | $3.28 | |||||||||
Generic Drugs ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,107.80 | 0.55 | % | $2.89 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,022.19 | 0.55 | % | $2.77 | |||||||||
Pharmaceutical ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 987.60 | 0.36 | % | $1.78 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,023.14 | 0.36 | % | $1.82 | |||||||||
Retail ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,162.60 | 0.35 | % | $1.89 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,023.19 | 0.35 | % | $1.77 | |||||||||
Semiconductor ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,133.60 | 0.35 | % | $1.86 | |||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,023.19 | 0.35 | % | $1.77 |
* | Expenses are equal to the Fund’s annualized expense ratio (for the six months ended March 31, 2018) multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year divided by the number of days in the fiscal year (to reflect the one-half year period). |
** | Assumes annual return of 5% before expenses |
6 |
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 100.0% | ||||||||
Ireland: 1.6% | ||||||||
118,991 | Alkermes Plc (USD) * | $ | 6,896,718 | |||||
Netherlands: 2.7% | ||||||||
371,336 | QIAGEN NV (USD) * | 11,997,866 | ||||||
Spain: 2.4% | ||||||||
499,074 | Grifols SA (ADR) | 10,580,369 | ||||||
United States: 93.3% | ||||||||
172,056 | Alexion Pharmaceuticals, Inc. * | 19,177,362 | ||||||
147,680 | Allergan Plc | 24,853,067 | ||||||
67,245 | Alnylam Pharmaceuticals, Inc. * | 8,008,880 | ||||||
282,165 | Amgen, Inc. | 48,103,489 | ||||||
85,121 | Biogen Idec, Inc. * | 23,307,832 | ||||||
237,412 | BioMarin Pharmaceutical, Inc. * | 19,246,991 | ||||||
31,444 | Bluebird Bio, Inc. * | 5,369,063 | ||||||
356,566 | Celgene Corp. * | 31,809,253 | ||||||
79,883 | Charles River Laboratories International, Inc. * | 8,526,711 | ||||||
613,274 | Gilead Sciences, Inc. | 46,234,727 | ||||||
84,393 | Illumina, Inc. * | 19,952,193 | ||||||
222,428 | Incyte Corp. * | 18,534,925 | ||||||
115,186 | Ionis Pharmaceuticals, Inc. * | 5,077,399 | ||||||
200,020 | IQVIA Holdings, Inc. * | 19,623,962 | ||||||
172,081 | Nektar Therapeutics * | 18,285,327 | ||||||
104,240 | Neurocrine Biosciences, Inc. * | 8,644,623 | ||||||
61,064 | Regeneron Pharmaceuticals, Inc. * | 21,027,999 | ||||||
135,181 | Seattle Genetics, Inc. * | 7,075,374 | ||||||
169,121 | Shire Plc (ADR) | 25,264,986 | ||||||
40,397 | TESARO, Inc. * † | 2,308,285 | ||||||
64,089 | United Therapeutics Corp. * | 7,201,040 | ||||||
132,931 | Vertex Pharmaceuticals, Inc. * | 21,665,094 | ||||||
409,298,582 | ||||||||
Total
Common Stocks (Cost: $509,101,124) | 438,773,535 |
Number of Shares | Value | |||||||
MONEY MARKET FUND: 0.1% (Cost: $379,960) | ||||||||
379,960 | Dreyfus Government Cash Management Fund – Institutional Shares | $ | 379,960 | |||||
Total Investments Before Collateral for Securities Loaned: 100.1% (Cost: $509,481,084) | 439,153,495 | |||||||
Principal Amount | ||||||||
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 0.4% | ||||||||
Repurchase Agreements: 0.4% | ||||||||
$ | 1,000,000 | Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $1,000,201; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $1,020,000 including accrued interest) | 1,000,000 | |||||
542,625 | Repurchase agreement dated 3/29/18 with Mizuho Securities USA, Inc., 1.80%, due 4/2/18, proceeds $542,734; (collateralized by various U.S. government and agency obligations, 2.84% to 5.00%, due 12/1/24 to 12/15/47, valued at $553,478 including accrued interest) | 542,625 | ||||||
Total Short-Term Investments Held as Collateral for Securities on Loan (Cost: $1,542,625) | 1,542,625 | |||||||
Total Investments: 100.5% (Cost: $511,023,709) | 440,696,120 | |||||||
Liabilities in excess of other assets: (0.5)% | (2,044,592 | ) | ||||||
NET ASSETS: 100.0% | $ | 438,651,528 |
Definitions: | |
ADR | American Depositary Receipt |
USD | United States Dollar |
Footnotes: | |
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $1,465,812. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Biotechnology | 61.5 | % | $ | 270,280,804 | ||||
Health Care | 29.2 | 128,015,961 | ||||||
Life Sciences Tools & Services | 9.2 | 40,476,770 | ||||||
Money Market Fund | 0.1 | 379,960 | ||||||
100.0 | % | $ | 439,153,495 |
See Notes to Financial Statements
7 |
VANECK VECTORS BIOTECH ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks* | $ | 438,773,535 | $ | — | $ | — | $ | 438,773,535 | |||||||||
Money Market Fund | 379,960 | — | — | 379,960 | |||||||||||||
Repurchase Agreements | — | 1,542,625 | — | 1,542,625 | |||||||||||||
Total | $ | 439,153,495 | $ | 1,542,625 | $ | — | $ | 440,696,120 |
* See Schedule of Investments for geographic sector breakouts.
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
8 |
VANECK VECTORS ENVIRONMENTAL SERVICES ETF
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 100.0% | ||||||||
United Kingdom: 10.2% | ||||||||
23,150 | Steris Plc (USD) | $ | 2,161,284 | |||||
United States: 89.8% | ||||||||
24,439 | ABM Industries, Inc. | 818,218 | ||||||
37,258 | Advanced Disposal Services, Inc. * | 830,108 | ||||||
7,383 | Cantel Medical Corp. | 822,540 | ||||||
33,913 | Casella Waste Systems, Inc. * | 792,886 | ||||||
90,495 | Ceco Environmental Corp. | 402,703 | ||||||
16,516 | Clean Harbors, Inc. * | 806,146 | ||||||
55,012 | Covanta Holding Corp. † | 797,674 | ||||||
47,298 | Darling International, Inc. * | 818,255 | ||||||
18,566 | Donaldson Company, Inc. | 836,398 | ||||||
18,860 | Heritage-Crystal Clean, Inc. * | 444,153 | ||||||
27,659 | Layne Christensen Co. * † | 412,672 | ||||||
49,852 | Newpark Resources, Inc. * | 403,801 | ||||||
31,999 | Republic Services, Inc. | 2,119,294 | ||||||
12,610 | Schnitzer Steel Industries, Inc. | 407,934 | ||||||
13,797 | Stericycle, Inc. * † | 807,538 | ||||||
12,188 | Tennant Co. † | 825,128 | ||||||
15,224 | Tenneco, Inc. | 835,341 | ||||||
16,493 | Tetra Tech, Inc. | 807,332 | ||||||
15,393 | US Ecology, Inc. | 820,447 | ||||||
29,534 | Waste Connections, Inc. | 2,118,769 | ||||||
25,299 | Waste Management, Inc. | 2,128,152 | ||||||
19,055,489 | ||||||||
Total
Common Stocks (Cost: $19,471,613) | 21,216,773 | |||||||
MONEY
MARKET FUND: 0.3% (Cost: $52,946) | ||||||||
52,946 | Dreyfus Government Cash Management Fund – Institutional Shares | 52,946 | ||||||
Total
Investments Before Collateral for Securities Loaned: 100.3% (Cost: $19,524,559) | 21,269,719 |
Principal Amount |
Value | |||||||
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 8.0% | ||||||||
Repurchase Agreements: 8.0% | ||||||||
$ | 1,000,000 | Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $1,000,201; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $1,020,000 including accrued interest) | $ | 1,000,000 | ||||
704,843 | Repurchase agreement dated 3/29/18 with HSBC Securities USA, Inc., 1.79%, due 4/2/18, proceeds $704,983; (collateralized by various U.S. government and agency obligations, 2.50% to 8.00%, due 4/1/22 to 3/1/48, valued at $719,851 including accrued interest) | 704,843 | ||||||
Total Short-Term Investments Held as Collateral for Securities
on Loan (Cost: $1,704,843) | 1,704,843 | |||||||
Total Investments: 108.3% (Cost: $21,229,402) | 22,974,562 | |||||||
Liabilities in excess of other assets: (8.3)% | (1,757,273 | ) | ||||||
NET ASSETS: 100.0% | $ | 21,217,289 |
Definitions: | |
USD | United States Dollar |
Footnotes: | |
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $1,680,079. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Consumer Discretionary | 3.9 | % | $ | 835,341 | ||||
Consumer Staples | 3.9 | 818,255 | ||||||
Energy | 1.9 | 403,801 | ||||||
Health Care | 14.0 | 2,983,824 | ||||||
Industrials | 74.2 | 15,767,618 | ||||||
Materials | 1.9 | 407,934 | ||||||
Money Market Fund | 0.2 | 52,946 | ||||||
100.0 | % | $ | 21,269,719 |
See Notes to Financial Statements
9 |
VANECK VECTORS ENVIRONMENTAL SERVICES ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks* | $ | 21,216,773 | $ | — | $ | — | $ | 21,216,773 | |||||||||
Money Market Fund | 52,946 | — | — | 52,946 | |||||||||||||
Repurchase Agreements | — | 1,704,843 | — | 1,704,843 | |||||||||||||
Total | $ | 21,269,719 | $ | 1,704,843 | $ | — | $ | 22,974,562 |
* See Schedule of Investments for geographic sector breakouts.
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
10 |
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number | ||||||||
of Shares | Value | |||||||
COMMON STOCKS: 97.3% | ||||||||
Australia: 12.5% | ||||||||
170,561 | Aristocrat Leisure Ltd. # | $ | 3,180,319 | |||||
97,286 | Crown Ltd. # | 954,208 | ||||||
185,971 | Star Entertainment Group Ltd. # | 760,302 | ||||||
506,146 | TABCORP Holdings Ltd. # | 1,714,159 | ||||||
6,608,988 | ||||||||
Cambodia: 1.0% | ||||||||
522,000 | Nagacorp Ltd. # | 543,372 | ||||||
Canada: 1.3% | ||||||||
25,891 | Stars Group, Inc. (USD) * | 713,297 | ||||||
China / Hong Kong: 26.6% | ||||||||
510,240 | Galaxy Entertainment Group Ltd. # | 4,683,244 | ||||||
22,620,000 | Landing International Development Ltd. * # | 635,520 | ||||||
74,013 | Melco Crown Entertainment Ltd. (ADR) | 2,144,897 | ||||||
194,000 | Melco International Development Ltd. # | 569,340 | ||||||
256,900 | MGM China Holdings Ltd. † # | 668,155 | ||||||
644,000 | Sands China Ltd. # | 3,499,644 | ||||||
663,000 | SJM Holdings Ltd. # | 580,839 | ||||||
366,800 | Wynn Macau Ltd. # | 1,344,382 | ||||||
14,126,021 | ||||||||
Greece: 1.4% | ||||||||
65,620 | OPAP SA # | 751,729 | ||||||
Ireland: 3.6% | ||||||||
18,534 | Paddy Power Betfair Plc | 1,902,163 | ||||||
Japan: 3.4% | ||||||||
17,500 | Heiwa Corp. # | 345,228 | ||||||
14,879 | Sankyo Co. Ltd. # | 520,773 | ||||||
56,400 | Sega Sammy Holdings, Inc. # | 914,284 | ||||||
1,780,285 | ||||||||
Malaysia: 2.1% | ||||||||
886,098 | Genting Malaysia Bhd # | 1,113,626 | ||||||
Malta: 1.2% | ||||||||
45,218 | Kindred Group Plc (LDR) # | 618,520 | ||||||
New Zealand: 0.7% | ||||||||
136,644 | Sky City Entertainment Group Ltd. # | 385,658 | ||||||
Singapore: 2.7% | ||||||||
1,738,100 | Genting Singapore Plc # | 1,441,457 | ||||||
South Africa: 0.7% | ||||||||
183,225 | Tsogo Sun Holdings Ltd. # | 359,713 | ||||||
South Korea: 2.0% | ||||||||
30,215 | Kangwon Land, Inc. # | 774,589 | ||||||
15,636 | Paradise Co. Ltd. # | 301,975 | ||||||
1,076,564 | ||||||||
Sweden: 0.9% | ||||||||
31,504 | Betsson AB # | 237,890 | ||||||
50,713 | NetEnt AB # | 255,236 | ||||||
493,126 | ||||||||
United Kingdom: 5.7% | ||||||||
111,850 | GVC Holdings Plc † # | 1,445,064 | ||||||
59,433 | Playtech Ltd. # | 611,173 | ||||||
206,701 | William Hill Plc # | 958,249 | ||||||
3,014,486 |
Number | ||||||||
of Shares | Value | |||||||
United States: 31.5% | ||||||||
17,962 | Boyd Gaming Corp. | $ | 572,269 | |||||
186,986 | Caesars Entertainment Corp. * | 2,103,592 | ||||||
2,530 | Churchill Downs, Inc. | 617,446 | ||||||
15,889 | Eldorado Resorts, Inc. * † | 524,337 | ||||||
30,455 | International Game Technology Plc | 814,062 | ||||||
59,180 | Las Vegas Sands Corp. | 4,255,042 | ||||||
108,496 | MGM Resorts International | 3,799,530 | ||||||
15,199 | Penn National Gaming, Inc. * | 399,126 | ||||||
10,496 | Scientific Games Corp. * † | 436,634 | ||||||
17,646 | Wynn Resorts Ltd. | 3,217,925 | ||||||
16,739,963 | ||||||||
Total
Common Stocks (Cost: $50,518,588) |
51,668,968 | |||||||
REAL ESTATE
INVESTMENT TRUSTS: 2.8% (Cost: $1,586,127) | ||||||||
United States: 2.8% | ||||||||
43,206 | Gaming and Leisure Properties, Inc. | 1,446,105 | ||||||
Total
Investments Before Collateral for Securities Loaned: 100.1% (Cost: $52,104,715) | 53,115,073 | |||||||
Principal | ||||||||
Amount | ||||||||
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 4.2% | ||||||||
Repurchase Agreements: 4.2% | ||||||||
$ | 239,962 | Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.80%, due 4/2/18, proceeds $240,010; (collateralized by various U.S. government and agency obligations, 0.00% to 4.75%, due 4/12/18 to 9/9/49, valued at $244,761 including accrued interest) | 239,962 | |||||
1,000,000 | Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $1,000,201; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $1,020,000 including accrued interest) | 1,000,000 | ||||||
1,000,000 | Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $1,000,202; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $1,020,000 including accrued interest) | 1,000,000 | ||||||
Total
Short-Term Investments Held as
Collateral for Securities on Loan (Cost: $2,239,962) | 2,239,962 | |||||||
Total
Investments: 104.3% (Cost: $54,344,677) | 55,355,035 | |||||||
Liabilities in excess of other assets: (4.3)% | (2,264,512 | ) | ||||||
NET ASSETS: 100.0% | $ | 53,090,523 |
See Notes to Financial Statements
11 |
VANECK VECTORS GAMING ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
Definitions:
ADR | American Depositary Receipt |
LDR | Local Depositary Receipt |
USD | United States Dollar |
Footnotes:
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $2,144,566. |
# | Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $30,168,648 which represents 56.8% of net assets. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Consumer Discretionary | 95.6 | % | $ | 50,778,212 | ||||
Information Technology | 1.7 | 890,756 | ||||||
Real Estate | 2.7 | 1,446,105 | ||||||
100.0 | % | $ | 53,115,073 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 2 | Level 3 | ||||||||||||||||
Level 1 | Significant | Significant | |||||||||||||||
Quoted | Observable | Unobservable | |||||||||||||||
Prices | Inputs | Inputs | Value | ||||||||||||||
Common Stocks | |||||||||||||||||
Australia | $ | — | $ | 6,608,988 | $ | — | $ | 6,608,988 | |||||||||
Cambodia | — | 543,372 | — | 543,372 | |||||||||||||
Canada | 713,297 | — | — | 713,297 | |||||||||||||
China / Hong Kong | 2,144,897 | 11,981,124 | — | 14,126,021 | |||||||||||||
Greece | — | 751,729 | — | 751,729 | |||||||||||||
Ireland | 1,902,163 | — | — | 1,902,163 | |||||||||||||
Japan | — | 1,780,285 | — | 1,780,285 | |||||||||||||
Malaysia | — | 1,113,626 | — | 1,113,626 | |||||||||||||
Malta | — | 618,520 | — | 618,520 | |||||||||||||
New Zealand | — | 385,658 | — | 385,658 | |||||||||||||
Singapore | — | 1,441,457 | — | 1,441,457 | |||||||||||||
South Africa | — | 359,713 | — | 359,713 | |||||||||||||
South Korea | — | 1,076,564 | — | 1,076,564 | |||||||||||||
Sweden | — | 493,126 | — | 493,126 | |||||||||||||
United Kingdom | — | 3,014,486 | — | 3,014,486 | |||||||||||||
United States | 16,739,963 | — | — | 16,739,963 | |||||||||||||
Real Estate Investment Trusts* | 1,446,105 | — | — | 1,446,105 | |||||||||||||
Repurchase Agreements | — | 2,239,962 | — | 2,239,962 | |||||||||||||
Total | $ | 22,946,425 | $ | 32,408,610 | $ | — | $ | 55,355,035 |
* See Schedule of Investments for geographic sector breakouts.
During the period ended March 31, 2018, transfers of securities from Level 1 to Level 2 were $4,313,953. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements
See Notes to Financial Statements
12 |
VANECK VECTORS GENERIC DRUGS ETF
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number | ||||||||
of Shares | Value | |||||||
COMMON STOCKS: 100.1% | ||||||||
Belgium: 4.6% | ||||||||
2,057 | UCB SA # | $ | 167,437 | |||||
China / Hong Kong: 13.1% | ||||||||
66,000 | CSPC Pharmaceutical Group Ltd. # | 177,901 | ||||||
1,600 | Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. # | 4,963 | ||||||
5,000 | Shanghai Fosun Pharmaceutical Group Co. Ltd. # | 30,975 | ||||||
9,700 | Shanghai Pharmaceuticals Holding Co. Ltd. # | 26,110 | ||||||
89,000 | Sino Biopharmaceutical Ltd. # | 176,875 | ||||||
12,800 | Sinopharm Group Co. Ltd. | 64,095 | ||||||
480,919 | ||||||||
Finland: 0.9% | ||||||||
1,102 | Orion OYJ # | 33,719 | ||||||
Germany: 1.8% | ||||||||
659 | Stada Arzneimittel AG | 67,788 | ||||||
Hungary: 1.1% | ||||||||
1,971 | Richter Gedeon Nyrt # | 41,191 | ||||||
India: 16.0% | ||||||||
6,197 | Aurobindo Pharma Ltd. # | 53,392 | ||||||
6,346 | Biocon Ltd. # | 58,160 | ||||||
10,829 | Cadila Healthcare Ltd. # | 63,239 | ||||||
8,516 | Cipla Ltd. # | 71,390 | ||||||
1,754 | Dr Reddy’s Laboratories Ltd. (ADR) | 57,338 | ||||||
4,782 | Lupin Ltd. # | 54,228 | ||||||
25,378 | Sun Pharmaceuticals Industries Ltd. # | 193,978 | ||||||
1,790 | Torrent Pharmaceuticals Ltd. # | 34,489 | ||||||
586,214 | ||||||||
Indonesia: 1.5% | ||||||||
495,800 | Kalbe Farma Tbk PT # | 54,188 | ||||||
Ireland: 7.8% | ||||||||
1,652 | Alkermes Plc (USD) * | 95,750 | ||||||
572 | ICON Plc (USD) * | 67,576 | ||||||
1,490 | Perrigo Co. Plc (USD) | 124,177 | ||||||
287,503 | ||||||||
Israel: 6.2% | ||||||||
424 | Taro Pharmaceutical Industries Ltd. (USD) * | 41,866 | ||||||
10,756 | Teva Pharmaceutical Industries Ltd. (ADR) | 183,820 | ||||||
225,686 | ||||||||
Japan: 8.4% | ||||||||
1,000 | Hisamitsu Pharmaceutical Co., Inc. # | 77,343 | ||||||
6,100 | Kyowa Hakko Kirin Co. Ltd. # | 132,546 | ||||||
1,000 | Taisho Pharmaceutical Holdings Co. Ltd. # | 98,918 | ||||||
308,807 | ||||||||
Jordan: 1.2% | ||||||||
2,546 | Hikma Pharmaceuticals Plc (GBP) † # | 43,293 | ||||||
South Africa: 2.9% | ||||||||
4,828 | Aspen Pharmacare Holdings Ltd. # | 105,845 |
Number | ||||||||
of Shares | Value | |||||||
South Korea: 9.6% | ||||||||
981 | Celltrion, Inc. * # | $ | 293,463 | |||||
672 | Hanmi Science Co. Ltd. # | 60,067 | ||||||
353,530 | ||||||||
Switzerland: 5.1% | ||||||||
788 | Lonza Group AG # | 185,531 | ||||||
United States: 19.9% | ||||||||
1,170 | Albemarle Corp. † | 108,506 | ||||||
502 | Charles River Laboratories International, Inc. * | 53,584 | ||||||
2,203 | IQVIA Holdings, Inc. * | 216,136 | ||||||
913 | Mallinckrodt Plc * † | 13,220 | ||||||
5,445 | Mylan NV * | 224,171 | ||||||
5,918 | Opko Health, Inc. * † | 18,760 | ||||||
675 | PRA Health Sciences, Inc. * | 55,998 | ||||||
1,104 | Syneos Health, Inc. * | 39,192 | ||||||
729,567 | ||||||||
Total
Common Stocks (Cost: $3,518,125) | 3,671,218 | |||||||
MONEY
MARKET FUND: 1.2% (Cost: $44,394) | ||||||||
44,394 | Dreyfus Government Cash Management Fund – Institutional Shares | 44,394 | ||||||
Total Investments Before Collateral for Securities Loaned: 101.3% (Cost: $3,562,519) | 3,715,612 | |||||||
Principal Amount | ||||||||
SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES ON LOAN: 4.7% (Cost: $170,345) | ||||||||
Repurchase Agreement: 4.7% | ||||||||
$ | 170,345 | Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.80%, due 4/2/18, proceeds $170,379; (collateralized by various U.S. government and agency obligations, 0.00% to 4.75%, due 4/12/18 to 9/9/49, valued at $173,752 including accrued interest) | 170,345 | |||||
Total
Investments: 106.0% (Cost: $3,732,864) | 3,885,957 | |||||||
Liabilities in excess of other assets: (6.0)% | (218,669 | ) | ||||||
NET ASSETS: 100.0% | $ | 3,667,288 |
See Notes to Financial Statements
13 |
VANECK VECTORS GENERIC DRUGS ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
Definitions:
ADR | American Depositary Receipt |
GBP | British Pound |
USD | United States Dollar |
Footnotes:
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $170,906. |
# | Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $2,239,241 which represents 61.1% of net assets. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Biotechnology | 12.6 | % | $ | 466,133 | ||||
Health Care Distributors | 2.4 | 90,205 | ||||||
Life Sciences Tools & Services | 16.6 | 618,017 | ||||||
Pharmaceuticals | 64.3 | 2,388,357 | ||||||
Specialty Chemicals | 2.9 | 108,506 | ||||||
Money Market Fund | 1.2 | 44,394 | ||||||
100.0 | % | $ | 3,715,612 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks | |||||||||||||||||
Belgium | $ | — | $ | 167,437 | $ | — | $ | 167,437 | |||||||||
China / Hong Kong | 64,095 | 416,824 | — | 480,919 | |||||||||||||
Finland | — | 33,719 | — | 33,719 | |||||||||||||
Germany | 67,788 | — | — | 67,788 | |||||||||||||
Hungary | — | 41,191 | — | 41,191 | |||||||||||||
India | 57,338 | 528,876 | — | 586,214 | |||||||||||||
Indonesia | — | 54,188 | — | 54,188 | |||||||||||||
Ireland | 287,503 | — | — | 287,503 | |||||||||||||
Israel | 225,686 | — | — | 225,686 | |||||||||||||
Japan | — | 308,807 | — | 308,807 | |||||||||||||
Jordan | — | 43,293 | — | 43,293 | |||||||||||||
South Africa | — | 105,845 | — | 105,845 | |||||||||||||
South Korea | — | 353,530 | — | 353,530 | |||||||||||||
Switzerland | — | 185,531 | — | 185,531 | |||||||||||||
United States | 729,567 | — | — | 729,567 | |||||||||||||
Money Market Fund | 44,394 | — | — | 44,394 | |||||||||||||
Repurchase Agreement | — | 170,345 | — | 170,345 | |||||||||||||
Total | $ | 1,476,371 | $ | 2,409,586 | $ | — | $ | 3,885,957 |
During the period ended March 31, 2018, transfers of securities from Level 1 to Level 2 were $154,390, and transfers of securities from Level 2 to Level 1 were $53,386. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.
See Notes to Financial Statements
14 |
VANECK VECTORS PHARMACEUTICAL ETF
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 99.6% | ||||||||
Denmark: 5.0% | ||||||||
247,277 | Novo-Nordisk AS (ADR) | $ | 12,178,392 | |||||
France: 5.1% | ||||||||
313,775 | Sanofi SA (ADR) | 12,576,102 | ||||||
Ireland: 10.2% | ||||||||
343,897 | Endo International Plc (USD) * | 2,042,748 | ||||||
77,553 | Jazz Pharmaceuticals Plc (USD) * | 11,709,727 | ||||||
135,984 | Perrigo Co. Plc (USD) | 11,332,907 | ||||||
25,085,382 | ||||||||
Israel: 4.1% | ||||||||
590,857 | Teva Pharmaceutical Industries Ltd. (ADR) † | 10,097,746 | ||||||
Switzerland: 5.0% | ||||||||
152,995 | Novartis AG (ADR) | 12,369,646 | ||||||
United Kingdom: 12.6% | ||||||||
371,391 | AstraZeneca Plc (ADR) | 12,987,543 | ||||||
336,007 | GlaxoSmithKline Plc (ADR) † | 13,127,794 | ||||||
42,052 | GW Pharmaceuticals Plc (ADR) * | 4,737,999 | ||||||
30,853,336 | ||||||||
United States: 57.6% | ||||||||
109,132 | AbbVie, Inc. | 10,329,344 | ||||||
160,727 | Akorn, Inc. * | 3,007,202 | ||||||
117,862 | AmerisourceBergen Corp. | 10,160,883 | ||||||
189,405 | Bristol-Myers Squibb Co. | 11,979,866 | ||||||
208,394 | Catalent, Inc. * | 8,556,658 | ||||||
145,502 | Eli Lilly & Co. | 11,257,490 | ||||||
97,022 | Johnson & Johnson | 12,433,369 | ||||||
124,904 | Mallinckrodt Plc * † | 1,808,610 | ||||||
74,251 | McKesson Corp. | 10,459,738 | ||||||
229,844 | Merck and Co., Inc. | 12,519,603 | ||||||
265,183 | Mylan NV * | 10,917,584 | ||||||
123,638 | Patterson Companies, Inc. † | 2,748,473 | ||||||
348,445 | Pfizer, Inc. | 12,366,313 | ||||||
723,123 | Valeant Pharmaceuticals International, Inc. * † | 11,512,118 | ||||||
137,814 | Zoetis, Inc. | 11,508,847 | ||||||
141,566,098 | ||||||||
Total Common Stocks (Cost: $325,158,768) | 244,726,702 | |||||||
MONEY MARKET FUND: 0.1% (Cost: $253,687) | ||||||||
253,687 | Dreyfus Government Cash Management Fund – Institutional Shares | 253,687 | ||||||
Total Investments Before Collateral for Securities Loaned: 99.7% (Cost: $325,412,455) | 244,980,389 |
Principal Amount | Value |
|||||||
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 11.7% | ||||||||
Repurchase Agreements: 11.7% | ||||||||
$ | 6,846,752 | Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $6,848,137; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $6,983,687 including accrued interest) | $ | 6,846,752 | ||||
1,440,198 | Repurchase agreement dated 3/29/18 with Credit Agricole CIB, 1.75%, due 4/2/18, proceeds $1,440,478; (collateralized by various U.S. government and agency obligations, 1.50% to 1.63%, due 12/31/18 to 10/15/20, valued at $1,469,002 including accrued interest) | 1,440,198 | ||||||
6,846,752 | Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $6,848,129; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $6,983,687 including accrued interest) | 6,846,752 | ||||||
6,846,752 | Repurchase agreement dated 3/29/18 with HSBC Securities USA, Inc., 1.78%, due 4/2/18, proceeds $6,848,106; (collateralized by various U.S. government and agency obligations, 0.00% to 7.25%, due 5/15/18 to 1/15/37, valued at $7,008,651 including accrued interest) | 6,846,752 | ||||||
6,846,752 | Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $6,848,137; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $6,983,687 including accrued interest) | 6,846,752 | ||||||
Total Short-Term Investments Held as Collateral for Securities on Loan (Cost: $28,827,206) | 28,827,206 | |||||||
Total Investments: 111.4% (Cost: $354,239,661) | 273,807,595 | |||||||
Liabilities in excess of other assets: (11.4)% | (27,921,736 | ) | ||||||
NET ASSETS: 100.0% | $ | 245,885,859 |
See Notes to Financial Statements
15 |
VANECK VECTORS PHARMACEUTICAL ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
Definitions:
ADR | American Depositary Receipt |
USD | United States Dollar |
Footnotes:
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $28,238,597. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Health Care | 24.9 | % | $ | 61,099,672 | ||||
Pharmaceuticals | 75.0 | 183,627,030 | ||||||
Money Market Fund | 0.1 | 253,687 | ||||||
100.0 | % | $ | 244,980,389 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks* | $ | 244,726,702 | $ | — | $ | — | $ | 244,726,702 | |||||||||
Money Market Fund | 253,687 | — | — | 253,687 | |||||||||||||
Repurchase Agreements | — | 28,827,206 | — | 28,827,206 | |||||||||||||
Total | $ | 244,980,389 | $ | 28,827,206 | $ | — | $ | 273,807,595 |
* See Schedule of Investments for geographic sector breakouts.
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
16 |
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 100.1% | ||||||||
China / Hong Kong: 2.9% | ||||||||
47,792 | JD.com, Inc. (ADR) * | $ | 1,935,098 | |||||
United States: 97.2% | ||||||||
8,967 | Amazon.com, Inc. * | 12,978,298 | ||||||
12,779 | AmerisourceBergen Corp. | 1,101,678 | ||||||
1,591 | AutoZone, Inc. * | 1,032,066 | ||||||
17,006 | Best Buy Co., Inc. | 1,190,250 | ||||||
18,308 | Cardinal Health, Inc. | 1,147,545 | ||||||
18,486 | Costco Wholesale Corp. | 3,483,317 | ||||||
46,174 | CVS Caremark Corp. | 2,872,484 | ||||||
16,057 | Dollar General Corp. | 1,502,132 | ||||||
17,411 | Dollar Tree, Inc. * | 1,652,304 | ||||||
42,617 | Home Depot, Inc. | 7,596,054 | ||||||
10,735 | Kohl’s Corp. | 703,250 | ||||||
66,403 | Kroger Co. | 1,589,688 | ||||||
13,729 | L Brands, Inc. | 524,585 | ||||||
40,223 | Lowe’s Cos, Inc. | 3,529,568 | ||||||
23,545 | MACY’S, Inc. | 700,228 | ||||||
14,562 | McKesson Corp. | 2,051,349 | ||||||
6,144 | O’Reilly Automotive, Inc. * | 1,519,903 | ||||||
28,062 | Ross Stores, Inc. | 2,188,275 | ||||||
36,335 | Sysco Corp. | 2,178,647 | ||||||
38,744 | Target Corp. | 2,689,996 | ||||||
25,588 | The Gap, Inc. | 798,346 | ||||||
37,725 | TJX Cos., Inc. | 3,076,851 | ||||||
44,852 | Walgreens Boots Alliance, Inc. | 2,936,460 | ||||||
71,162 | Wal-Mart Stores, Inc. | 6,331,283 | ||||||
65,374,557 | ||||||||
Total Common Stocks (Cost: $72,260,522) | 67,309,655 |
Number of Shares | Value | |||||||
MONEY MARKET FUND: 0.0% | ||||||||
(Cost: $7,123) | ||||||||
7,123 | Dreyfus Government Cash Management Fund – Institutional Shares | $ | 7,123 | |||||
Total Investments: 100.1% (Cost: $72,267,645) | 67,316,778 | |||||||
Liabilities in excess of other assets: (0.1)% | (72,295 | ) | ||||||
NET ASSETS: 100.0% | $ | 67,244,483 |
Definitions:
ADR | American Depositary Receipt |
Footnotes: | |
* | Non-income producing |
Summary of Investments by Sector | % of Investments | Value | ||||||
Consumer Discretionary | 64.8 | % | $ | 43,617,204 | ||||
Consumer Staples | 28.8 | 19,391,879 | ||||||
Health Care | 6.4 | 4,300,572 | ||||||
Money Market Fund | 0.0 | 7,123 | ||||||
100.0 | % | $ | 67,316,778 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | |||||||||||||||
Common Stocks* | $ | 67,309,655 | $ | — | $ | — | $ | 67,309,655 | ||||||||||
Money Market Fund | 7,123 | — | — | 7,123 | ||||||||||||||
Total | $ | 67,316,778 | $ | — | $ | — | $ | 67,316,778 |
* See Schedule of Investments for geographic sector breakouts.
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
17 |
VANECK VECTORS SEMICONDUCTOR ETF
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 99.9% | ||||||||
Bermuda: 2.2% | ||||||||
1,110,912 | Marvell Technology Group Ltd. (USD) | $ | 23,329,152 | |||||
Netherlands: 9.6% | ||||||||
274,091 | ASML Holding NV (USD) | 54,423,509 | ||||||
409,721 | NXP Semiconductors NV (USD) * | 47,937,357 | ||||||
102,360,866 | ||||||||
Taiwan: 7.8% | ||||||||
1,919,727 | Taiwan Semiconductor Manufacturing Co. Ltd. (ADR) | 84,007,254 | ||||||
United States: 80.3% | ||||||||
2,529,691 | Advanced Micro Devices, Inc. * † | 25,423,395 | ||||||
546,899 | Analog Devices, Inc. | 49,838,906 | ||||||
949,700 | Applied Materials, Inc. | 52,812,817 | ||||||
227,502 | Broadcom Ltd. | 53,610,846 | ||||||
643,229 | Cadence Design Systems, Inc. * | 23,651,530 | ||||||
163,738 | Cavium, Inc. * | 12,997,522 | ||||||
1,665,398 | Intel Corp. | 86,733,928 | ||||||
387,959 | KLA-Tencor Corp. | 42,291,411 | ||||||
239,817 | Lam Research Corp. | 48,721,222 | ||||||
687,016 | Maxim Integrated Products, Inc. | 41,372,104 | ||||||
530,895 | Microchip Technology, Inc. † | 48,502,567 | ||||||
1,045,671 | Micron Technology, Inc. * | 54,521,286 | ||||||
267,700 | Microsemi Corp. * | 17,325,544 | ||||||
234,138 | NVIDIA Corp. | 54,224,019 | ||||||
966,701 | ON Semiconductor Corp. * | 23,645,506 | ||||||
212,122 | Qorvo, Inc. * † | 14,943,995 | ||||||
899,908 | Qualcomm, Inc. | 49,863,902 | ||||||
433,737 | Skyworks Solutions, Inc. | 43,486,472 | ||||||
529,237 | Teradyne, Inc. | 24,191,423 | ||||||
519,401 | Texas Instruments, Inc. | 53,960,570 | ||||||
537,532 | Xilinx, Inc. | 38,831,312 | ||||||
860,950,277 | ||||||||
Total Common Stocks (Cost: $1,160,384,582) | 1,070,647,549 | |||||||
MONEY MARKET FUND: 0.1% (Cost: $1,253,516) | ||||||||
1,253,516 | Dreyfus Government Cash Management Fund – Institutional Shares | 1,253,516 | ||||||
Total Investments Before Collateral for Securities Loaned: 100.0% (Cost: $1,161,638,098) | 1,071,901,065 |
Principal Amount | Value | |||||||
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES ON LOAN: 2.7% | ||||||||
Repurchase Agreements: 2.7% | ||||||||
$ | 6,909,356 | Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $6,910,753; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $7,047,543 including accrued interest) | $ | 6,909,356 | ||||
1,452,971 | Repurchase agreement dated 3/29/18 with Credit Agricole CIB, 1.75%, due 4/2/18, proceeds $1,453,254; (collateralized by various U.S. government and agency obligations, 1.50% to 1.63%, due 12/31/18 to 10/15/20, valued at $1,482,031 including accrued interest) | 1,452,971 | ||||||
6,909,356 | Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $6,910,746; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $7,047,543 including accrued interest) | 6,909,356 | ||||||
6,909,356 | Repurchase agreement dated 3/29/18 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.81%, due 4/2/18, proceeds $6,910,746; (collateralized by various U.S. government and agency obligations, 0.00% to 4.50%, due 12/1/26 to 4/1/48, valued at $7,047,543 including accrued interest) | 6,909,356 | ||||||
6,909,356 | Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $6,910,753; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $7,047,543 including accrued interest) | 6,909,356 | ||||||
Total Short-Term Investments Held as Collateral for Securities on Loan (Cost: $29,090,395) | 29,090,395 | |||||||
Total Investments: 102.7% (Cost: $1,190,728,493) | 1,100,991,460 | |||||||
Liabilities in excess of other assets: (2.7)% | (29,287,783 | ) | ||||||
NET ASSETS: 100.0% | $ | 1,071,703,677 |
See Notes to Financial Statements
18 |
Definitions: | |
ADR | American Depositary Receipt |
USD | United States Dollar |
Footnotes: | |
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $28,540,980. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned |
% of Investments | Value | ||||||
Information Technology | 16.1 | % | $ | 172,393,339 | ||||
Semiconductor Equipment | 20.8 | 222,440,382 | ||||||
Semiconductors | 63.0 | 675,813,828 | ||||||
Money Market Fund | 0.1 | 1,253,516 | ||||||
100.0 | % | $ | 1,071,901,065 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks* | $ | 1,070,647,549 | $ | — | $ | — | $ | 1,070,647,549 | |||||||||
Money Market Fund | 1,253,516 | — | — | 1,253,516 | |||||||||||||
Repurchase Agreements | — | 29,090,395 | — | 29,090,395 | |||||||||||||
Total | $ | 1,071,901,065 | $ | 29,090,395 | $ | — | $ | 1,100,991,460 |
* | See Schedule of Investments for geographic sector breakouts. |
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
19 |
VANECK VECTORS ETF TRUST
STATEMENTS OF ASSETS AND LIABILITIES
March 31, 2018 (unaudited)
See Notes to Financial Statements
20 |
VANECK VECTORS ETF TRUST
STATEMENTS OF ASSETS AND LIABILITIES
March 31, 2018 (unaudited)
See Notes to Financial Statements
21 |
VANECK VECTORS ETF TRUST
For the Six Months Ended March 31, 2018 (unaudited)
See Notes to Financial Statements
22 |
VANECK VECTORS ETF TRUST
STATEMENTS OF OPERATIONS
For the Six Months Ended March 31, 2018 (unaudited)
See Notes to Financial Statements
23 |
VANECK VECTORS ETF TRUST
STATEMENTS OF CHANGES IN NET ASSETS
See Notes to Financial Statements
24 |
VANECK VECTORS ETF TRUST
STATEMENTS OF CHANGES IN NET ASSETS
See Notes to Financial Statements
25 |
VANECK VECTORS ETF TRUST
STATEMENTS OF CHANGES IN NET ASSETS
See Notes to Financial Statements
26 |
VANECK VECTORS ETF TRUST
For a share outstanding throughout each period:
(a) | Calculated based upon average shares outstanding |
(b) | Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares. |
(c) | Not Annualized |
(d) | Annualized |
(e) | Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions. |
(f) | Amount represents less than $0.005 per share |
See Notes to Financial Statements
27 |
VANECK VECTORS ETF TRUST
FINANCIAL HIGHLIGHTS
For a share outstanding throughout each period:
(a) | Calculated based upon average shares outstanding |
(b) | Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares. |
(c) | Not Annualized |
(d) | Annualized |
(e) | Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions. |
(f) | Commencement of operations |
See Notes to Financial Statements
28 |
VANECK VECTORS ETF TRUST
FINANCIAL HIGHLIGHTS
For a share outstanding throughout each period:
(a) | Calculated based upon average shares outstanding |
(b) | Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares. |
(c) | Not Annualized |
(d) | Annualized |
(e) | Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions. |
See Notes to Financial Statements
29 |
VANECK VECTORS ETF TRUST
FINANCIAL HIGHLIGHTS
For a share outstanding throughout each period:
(a) | Calculated based upon average shares outstanding |
(b) | Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares. |
(c) | Not Annualized |
(d) | Annualized |
(e) | Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions. |
(f) | 0.06% of total return, representing $0.04 per share, consisted of a payment by the Adviser (See Note 3). |
See Notes to Financial Statements
30 |
VANECK VECTORS ETF TRUST
March 31, 2018 (unaudited)
Note 1—Fund Organization—VanEck Vectors ETF Trust (the “Trust”) is registered under the Investment Company Act of 1940, as amended, as an open-end management investment company. The Trust was incorporated in Delaware as a statutory trust on March 15, 2001. The Trust operates as a series fund, and as of March 31, 2018, offers fifty-six investment portfolios, each of which represents a separate series of the Trust.
These financial statements relate only to the following investment portfolios: Biotech ETF, Environmental Services ETF, Gaming ETF, Generic Drugs ETF, Pharmaceutical ETF, Retail ETF and Semiconductor ETF (each a “Fund” and, together, the “Funds”). Each Fund was created to provide investors with the opportunity to purchase a security representing a proportionate undivided interest in a portfolio of securities consisting of substantially all of the common stocks in substantially the same weighting, in an index published by Indxx LLC, ICE Data Indices, LLC or MV Index Solutions GmbH (“MVIS”), a wholly owned subsidiary of Van Eck Associates Corporation (the “Adviser”).
The Funds’ respective indices are presented below:
Fund | Index |
Biotech ETF | MVIS® US Listed Biotech 25 Index* |
Environmental Services ETF | NYSE Arca Environmental Services Index |
Gaming ETF | MVIS® Global Gaming Index* |
Generic Drugs ETF | Indxx Global Generics & New Pharma Index |
Pharmaceutical ETF | MVIS® US Listed Pharmaceutical 25 Index* |
Retail ETF | MVIS® US Listed Retail 25 Index* |
Semiconductor ETF | MVIS® US Listed Semiconductor 25 Index* |
* | Published by MV Index Solutions GmbH |
Note 2—Significant Accounting Policies—The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.
The Funds are investment companies and are following accounting and reporting requirements of Accounting Standards Codification (“ASC”) 946 Financial Services — Investment Companies.
The following is a summary of significant accounting policies followed by the Funds.
A. | Security Valuation—The Funds value their investments in securities and other assets and liabilities at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Securities traded on national exchanges or traded on the NASDAQ National Market System are valued at the last sales price as reported at the close of each business day. Securities traded on the NASDAQ Stock Market are valued at the NASDAQ official closing price. Over-the-counter securities not included in the NASDAQ National Market System and listed securities for which no sale was reported are valued at the mean of the bid and ask prices. To the extent these securities are actively traded they are categorized as Level 1 in the fair value hierarchy (as described below). Certain foreign securities, whose values may be affected by market direction or events occurring before the Funds’ pricing time (4:00 p.m. Eastern Time) but after the last close of the securities’ primary market, are fair valued using a pricing service and are categorized as Level 2 in the fair value hierarchy. The pricing service, using methods approved by the Board of Trustees, considers the correlation of the trading patterns of the foreign security to intraday trading in the U.S. markets, based on indices of domestic securities and other appropriate indicators such as prices of relevant ADR’s and futures contracts. The Funds may also fair value securities in other situations, such as, when a particular foreign market is closed but the Fund is open. Short-term debt securities with sixty days or less to maturity are valued at amortized cost, which with accrued interest approximates fair value. Money market fund investments are valued at net asset value and are considered to be Level 1 in the fair value hierarchy. The Pricing Committee of the Adviser provides oversight of the Funds’ valuation policies and procedures, which are approved by the Funds’ Board of Trustees. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities dealers, and other market sources to determine fair value. The Pricing Committee convenes regularly to review the fair value of financial instruments or other assets. If market quotations for a security or other asset are not readily available, or if the Adviser believes it does not otherwise reflect the fair value of a security or asset, the security or asset will be fair valued by the Pricing Committee in accordance with the Funds’ valuation policies and |
31 |
VANECK VECTORS ETF TRUST
NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)
procedures. The Pricing Committee employs various methods for calibrating the valuation approaches utilized to determine fair value, including a regular review of key inputs and assumptions, periodic comparisons to valuations provided by other independent pricing services, transactional back-testing and disposition analysis.
Certain factors such as economic conditions, political events, market trends, the nature of and duration of any restrictions on disposition, trading in similar securities of the issuer or comparable issuers and other security specific information are used to determine the fair value of these securities. Depending on the relative significance of valuation inputs, these securities may be classified either as Level 2 or Level 3 in the fair value hierarchy. The price which the Funds may realize upon sale of an investment may differ materially from the value presented in the Schedules of Investments.
The Funds utilize various methods to measure the fair value of their investments on a recurring basis, which includes a hierarchy that prioritizes inputs to valuation methods used to measure fair value. The fair value hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The transfers between levels of the fair value hierarchy assume the financial instruments where transferred at the beginning of the reporting period. The three levels of the fair value hierarchy are described below:
Level 1 – Quoted prices in active markets for identical securities.
Level 2 – Significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
Level 3 – Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
A summary of the inputs, the levels used to value the Funds’ investments, and transfers between levels are located in the Schedules of Investments. Additionally, tables that reconcile the valuation of the Funds’ Level 3 investments and that present additional information about valuation methodologies and unobservable inputs, if applicable, are located in the Schedules of Investments.
B. | Federal Income Taxes—It is each Fund’s policy to comply with the provisions of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Therefore, no federal income tax provision is required. |
C. | Dividends and Distributions to Shareholders—Dividends to shareholders from net investment income and distributions from net realized capital gains, if any, are declared and paid annually by each Fund (except for dividends from net investment income on Pharmaceutical ETF, which are declared and paid quarterly). Income dividends and capital gain distributions are determined in accordance with U.S. income tax regulations, which may differ from such amounts determined in accordance with GAAP. |
D. | Currency Translation—Assets and liabilities denominated in foreign currencies and commitments under foreign currency contracts are translated into U.S. dollars at the closing prices of such currencies each business day as quoted by one or more sources. Purchases and sales of investments are translated at the exchange rates prevailing when such investments are acquired or sold. Foreign denominated income and expenses are translated at the exchange rates prevailing when accrued. The portion of realized and unrealized gains and losses on investments that result from fluctuations in foreign currency exchange rates is not separately disclosed in the financial statements. Recognized gains or losses attributable to foreign currency fluctuations on foreign currency denominated assets, other than investments, and liabilities are recorded as net realized gain (loss) on foreign currency transactions and foreign denominated assets and liabilities in the Statements of Operations. |
E. | Restricted Securities—The Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities, if any, is included at the end of each Fund’s Schedule of Investments. |
32 |
F. | Repurchase Agreements—The Funds may enter into repurchase agreements with financial institutions, deemed to be creditworthy by the Adviser, to generate income from their excess cash balances and to invest securities lending cash collateral. A repurchase agreement is an agreement under which a Fund acquires securities from a seller, subject to resale to the seller at an agreed upon price and date. A Fund, through its custodian/securities lending agent, takes possession of securities collateralizing the repurchase agreement. Pursuant to the terms of the repurchase agreement, such securities must have an aggregate market value greater than or equal to the terms of the repurchase price plus accrued interest at all times. If the value of the underlying securities falls below the value of the repurchase price plus accrued interest, the Funds will require the seller to deposit additional collateral by the next business day. If the request for additional collateral is not met, or the seller defaults on its repurchase obligation, the Funds maintain their right to sell the underlying securities at market value and may claim any resulting loss against the seller. Repurchase agreements held as of March 31, 2018 are reflected in the Schedules of Investments. |
G. | Offsetting Assets and Liabilities—In the ordinary course of business, the Funds enter into transactions subject to enforceable master netting or other similar agreements. Generally, the right of setoff in those agreements allows the Funds to set off any exposure to a specific counterparty with any collateral received or delivered to that counterparty based on the terms of the agreements. The Funds may pledge or receive cash and/or securities as collateral for derivative instruments, securities lending and repurchase agreements. For financial reporting purposes, the Funds present securities lending and repurchase agreement assets and liabilities on a gross basis in the Statements of Assets and Liabilities. Collateral held at March 31, 2018 is presented in the Schedules of Investments. Refer to related disclosures in Note 2F (Repurchase Agreements) and Note 9 (Securities Lending). |
H. | Other—Security transactions are accounted for on trade date. Realized gains and losses are determined based on the specific identification method. Dividend income is recorded on the ex-dividend date except that certain dividends from foreign securities are recognized upon notification of the ex-dividend date. Interest income, including amortization of premiums and discounts, is accrued as earned. |
In the normal course of business, the Funds enter into contracts that contain a variety of general indemnifications. The Funds’ maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Funds that have not yet occurred. However, the Adviser believes the risk of loss under these arrangements to be remote.
Note 3—Investment Management and Other Agreements—The Adviser is the investment adviser to the Funds. The Adviser receives a management fee, calculated daily and payable monthly based on an annual rate of each Fund’s average daily net assets. The Adviser has agreed, until at least February 1, 2019, to waive management fees and assume expenses to prevent each Fund’s total annual operating expenses (excluding acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses) from exceeding the expense limitations listed in the table below. Refer to the Statements of Operations for the amounts waived/assumed by the Adviser for the period ended March 31, 2018.
The current expense limitations and management fee rates are as follows:
Fund | Expense Limitations | Management Fee Rates | ||||||
Biotech ETF | 0.35 | % | 0.35 | % | ||||
Environmental Services ETF | 0.55 | 0.50 | ||||||
Gaming ETF | 0.65 | 0.50 | ||||||
Generic Drugs ETF | 0.55 | 0.50 | ||||||
Pharmaceutical ETF | 0.35 | 0.35 | ||||||
Retail ETF | 0.35 | 0.35 | ||||||
Semiconductor ETF | 0.35 | 0.35 |
During the year ended September 30, 2016, the Adviser voluntarily reimbursed the Semiconductor ETF $340,000 for transactional losses. The per share and total return impact to the Fund is reflected in the Financial Highlights.
In addition, Van Eck Securities Corporation (the “Distributor”), an affiliate of the Adviser, acts as the Funds’ distributor. Certain officers and a Trustee of the Trust are officers, directors or stockholders of the Adviser and Distributor.
33 |
VANECK VECTORS ETF TRUST
NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)
Note 4—Investments—For the period ended March 31, 2018, the cost of purchases and proceeds from sales of investments other than U.S. government obligations and short-term obligations (excluding in-kind transactions described in Note 6) were as follows:
Fund | Cost of Investments Purchased | Proceeds from Investments Sold | ||||||
Biotech ETF | $84,113,285 | $85,729,913 | ||||||
Environmental Services ETF | 2,210,087 | 2,304,141 | ||||||
Gaming ETF | 8,584,537 | 7,022,826 | ||||||
Generic Drugs ETF | 121,705 | 166,994 | ||||||
Pharmaceutical ETF | 23,128,123 | 23,179,553 | ||||||
Retail ETF | 9,065,529 | 9,538,423 | ||||||
Semiconductor ETF | 73,211,942 | 88,145,753 |
Note 5—Income Taxes—As of March 31, 2018, for Federal income tax purposes, the identified cost of investments owned, net unrealized appreciation (depreciation), gross unrealized appreciation, and gross unrealized depreciation of investments were as follows:
Fund | Cost of Investments | Gross Unrealized Appreciation | Gross Unrealized Depreciation | Net Unrealized Appreciation (Depreciation) | ||||||||||||
Biotech ETF | $ 512,008,932 | $21,014,142 | $(92,326,954 | ) | $(71,312,812 | ) | ||||||||||
Environmental Services ETF | 21,236,080 | 2,383,933 | (645,451 | ) | 1,738,482 | |||||||||||
Gaming ETF | 54,907,405 | 3,931,558 | (3,483,928 | ) | 447,630 | |||||||||||
Generic Drugs ETF | 3,761,677 | 756,826 | (632,546 | ) | 124,280 | |||||||||||
Pharmaceutical ETF | 354,242,100 | 1,465,825 | (81,900,330 | ) | (80,434,505 | ) | ||||||||||
Retail ETF | 72,302,254 | 3,258,660 | (8,244,136 | ) | (4,985,476 | ) | ||||||||||
Semiconductor ETF | 1,190,728,493 | 896,749 | (90,633,782 | ) | (89,737,033 | ) |
The tax character of dividends paid to shareholders during the year ended September 30, 2017 was as follows:
Fund | Ordinary Income | |||
Biotech ETF | $1,715,606 | |||
Environmental Services ETF | 132,750 | |||
Gaming ETF | 586,300 | |||
Generic Drugs ETF | 19,400 | |||
Pharmaceutical ETF | 5,854,105 | |||
Retail ETF | 1,772,514 | |||
Semiconductor ETF | 4,764,060 |
The tax character of current year distributions will be determined at the end of the current fiscal year.
At September 30, 2017, the Funds had capital loss carryforwards available to offset future capital gains, as follows:
Fund | Short-Term Capital Losses with No Expiration | Long-Term Capital Losses with No Expiration | Amount Expiring in the Year Ended September 30, 2018 | Total | ||||||||||||
Biotech ETF | $ | — | $ | (11,474,284 | ) | $ | — | $ | (11,474,284 | ) | ||||||
Environmental Services ETF | (539,614 | ) | (5,764,706 | ) | (479,375 | ) | (6,783,695 | ) | ||||||||
Gaming ETF | (2,187,113 | ) | (3,941,930 | ) | — | (6,129,043 | ) | |||||||||
Generic Drugs ETF | (120,655 | ) | (80,087 | ) | — | (200,742 | ) | |||||||||
Pharmaceutical ETF | (5,362,815 | ) | (6,716,207 | ) | — | (12,079,022 | ) | |||||||||
Retail ETF | (1,336,686 | ) | (1,417,095 | ) | — | (2,753,781 | ) | |||||||||
Semiconductor ETF | (1,648,128 | ) | (425,995 | ) | — | (2,074,123 | ) |
The Funds recognize the tax benefits of uncertain tax positions only where the position is “more-likely-than-not” to be sustained assuming examination by applicable tax authorities. Management has analyzed the Funds’ tax positions, and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on return filings for all open tax years. The Funds do not have exposure for additional years that might still be open in
34 |
certain foreign jurisdictions. Therefore, no provision for income tax is required in the Funds’ financial statements. However, certain Funds are subject to foreign taxes on the appreciation in value of certain investments. The Funds provide for such taxes on both realized and unrealized appreciation.
The Funds recognize interest and penalties, if any, related to uncertain tax positions as income tax expense in the Statements of Operations. During the period ended March 31, 2018, the Funds did not incur any interest or penalties.
Note 6—Capital Share Transactions—As of March 31, 2018, there was an unlimited number of capital shares of beneficial interest authorized by the Trust with no par value. Fund shares are not individually redeemable and are issued and redeemed at their net asset value per share only through certain authorized broker-dealers (“Authorized Participants”) in blocks of shares (“Creation Units”), consisting of 50,000 shares, or multiples thereof.
The consideration for the purchase or redemption of Creation Units of the Funds generally consists of the in-kind contribution or distribution of securities constituting the Funds’ underlying index (“Deposit Securities”) plus a balancing cash component to equate the transaction to the net asset value per share of the Fund on the transaction date. Cash may also be substituted in an amount equivalent to the value of certain Deposit Securities, generally as a result of market circumstances, or when the securities are not available in sufficient quantity for delivery or are not eligible for trading by the Authorized Participant. The Funds may issue Creation Units in advance of receipt of Deposit Securities subject to various conditions, including a requirement to maintain on deposit at the Custodian for the benefit of the Funds, collateral consisting of cash in the form of U.S. dollars at least equal to 115% of the daily marked to market value of the missing Deposit Securities.
Authorized Participants purchasing and redeeming Creation Units may pay transaction fees directly to The Bank of New York Mellon. In addition, the Funds may impose certain variable fees for creations and redemptions with respect to transactions in Creation Units for cash, or on transactions effected outside the clearing process, which are treated as increases in capital. These variable fees, if any, are reflected in share transactions in the Statements of Changes in Net Assets.
For the period ended March 31, 2018, the Funds had in-kind contributions and redemptions as follows:
Fund | In-Kind Contributions | In-Kind Redemptions | ||||||
Biotech ETF | $ | 32,368,213 | $ | 247,868,615 | ||||
Environmental Services ETF | 4,289,265 | — | ||||||
Gaming ETF | 30,073,511 | 4,417,017 | ||||||
Pharmaceutical ETF | 319,515,272 | 359,084,634 | ||||||
Retail ETF | 45,894,807 | 44,900,506 | ||||||
Semiconductor ETF | 7,666,956,464 | 7,497,866,780 |
The in-kind contributions and in-kind redemptions in this table represent the accumulation of each Fund’s daily net shareholder transactions including rebalancing activity, while the Statements of Changes in Net Assets reflect gross shareholder transactions including any cash component of the transactions.
Note 7—Concentration of Risk—The investment objective of each Fund is to seek investment results that correspond generally to the price and yield performance, before fees and expenses, of its underlying index, as indicated in the name of each Fund. The Adviser uses a “passive” or index approach to achieve each Fund’s investment objective by investing in a portfolio of securities that generally replicates the Fund’s index. Each of the Funds is classified as a non-diversified fund under the 1940 Act. Non-diversified funds generally hold securities of fewer issuers than diversified funds and may be more susceptible to the risks associated with these particular issuers, or to a single economic, political or regulatory occurrences affecting these issuers. The Funds may purchase securities on foreign exchanges. Securities of foreign issuers involve special risks and considerations not typically associated with investing in U.S. issuers. These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.
In March 2017, the United Kingdom triggered Article 50, and is now scheduled to leave the European Union (“EU”) by the end of March 2019. Significant uncertainty exists on how the withdrawal will take place, the terms of the withdrawal
35 |
VANECK VECTORS ETF TRUST
NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)
and the effects such withdrawal will have on the EU and the United Kingdom. This may further impact the value of the Euro and the British pound sterling, and has caused volatility and uncertainty in European and global markets.
A more complete description of risks is included in each Fund’s Prospectus and Statement of Additional Information.
Note 8—Trustee Deferred Compensation Plan—The Trust has a Deferred Compensation Plan (the “Plan”) for Trustees under which the Trustees can elect to defer receipt of their trustee fees until retirement, disability or termination from the Board of Trustees. The fees otherwise payable to the participating Trustees are deemed invested in shares of the Funds as directed by the Trustees.
The expense for the Plan is included in “Trustees’ fees and expenses” in the Statements of Operations. The liability for the Plan is shown as “Deferred Trustee fees” in the Statements of Assets and Liabilities.
Note 9—Securities Lending—To generate additional income, each of the Funds may lend its securities pursuant to a securities lending agreement with The Bank of New York Mellon, the securities lending agent and also the Funds’ custodian. Each Fund may lend up to 33% of its investments requiring that the loan be continuously collateralized by cash, U.S. government or U.S. government agency securities, shares of an investment trust or mutual fund, or any combination of cash and such securities at all times equal to at least 102% (105% for foreign securities) of the market value plus accrued interest on the securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled on the next business day. During the term of the loan, the Funds will continue to receive any dividends, interest or amounts equivalent thereto on the securities loaned, while receiving a fee from the borrower and/or earning interest on the investment of the cash collateral. Such fees and interest are shared with the securities lending agent under the terms of the securities lending agreement. The Funds may pay reasonable finders’, administrative and custodial fees in connection with a loan of its securities. Securities lending income is disclosed as such in the Statements of Operations. The collateral for securities loaned is recognized in the Schedules of Investments and the Statements of Assets and Liabilities. The cash collateral is maintained on the Funds’ behalf by the lending agent and is invested in repurchase agreements collateralized by obligations of the U.S. Treasury and/or Government Agencies. Loans are subject to termination at the option of the borrower or the Funds. Upon termination of the loan, the borrower will return to the lender securities identical to the securities loaned. The Funds bear the risk of delay in recovery of, or even loss of rights in, the securities loaned should the borrower of the securities fail financially. The value of loaned securities and related collateral outstanding at March 31, 2018 are presented on a gross basis in the Schedules of Investments and Statements of Assets and Liabilities.
The following table presents repurchase agreements held as collateral by type of security on loan pledged as of March 31, 2018:
Gross Amount of Recognized Liabilities for Securities Loaned in the Statements of Assets and Liabilities* | ||||
Fund | Equity Securities | |||
Biotech ETF | 1,542,625 | |||
Environmental Services ETF | 1,704,843 | |||
Gaming ETF | 2,239,962 | |||
Generic Drugs ETF | 170,345 | |||
Pharmaceutical ETF | 28,827,206 | |||
Semiconductor ETF | 29,090,395 |
* | Remaining contractual maturity of the agreements: overnight and continuous |
36 |
Note 10—Bank Line of Credit—The Funds may participate in a $200 million committed credit facility (the “Facility”) to be utilized for temporary financing until the settlement of sales or purchases of portfolio securities, the repurchase or redemption of shares of the Funds and other temporary or emergency purposes. The Funds have agreed to pay commitment fees, pro rata, based on the unused but available balance. Interest is charged to the Funds at rates based on prevailing market rates in effect at the time of borrowings. During the period ended March 31, 2018, the following Funds borrowed under this Facility:
Fund | Days Outstanding | Average
Daily Loan Balance | Average Interest Rate | Outstanding
Loan Balance as of March 31, 2018 | ||||||||||||
Biotech ETF | 54 | $ | 1,216,810 | 2.69 | % | $ | 455,842 | |||||||||
Gaming ETF | 52 | 154,834 | 2.87 | 146,004 | ||||||||||||
Pharmaceutical ETF | 127 | 696,070 | 2.68 | — | ||||||||||||
Retail ETF | 52 | 133,110 | 2.69 | 72,801 | ||||||||||||
Semiconductor ETF | 147 | 1,991,734 | 2.69 | — |
Note 11—Custodian Fees—The Funds have entered into an expense offset agreement with the custodian wherein they receive a credit toward the reduction of custodian fees whenever there are uninvested cash balances. The Funds could have invested their cash balances elsewhere if they had not agreed to a reduction in fees under the expense offset agreement with the custodian. For the period ended March 31, 2018, there were offsets to custodian fees and these amounts are reflected in custody expense in the Statements of Operations.
Note 12—Subsequent Events—The Funds have evaluated events and transactions for potential recognition or disclosure through the date the financial statements were issued.
37 |
This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by a VanEck Vectors ETF Trust (the “Trust”) Prospectus, which includes more complete information. An investor should consider the investment objective, risks, and charges and expenses of the Funds carefully before investing. The prospectus contains this and other information about the investment company. Please read the prospectus carefully before investing.
Additional information about the Trust’s Board of Trustees/Officers and a description of the policies and procedures the Trust uses to determine how to vote proxies relating to portfolio securities are provided in the Statement of Additional Information. The Statement of Additional Information and information regarding how the Trust voted proxies relating to portfolio securities during the most recent twelve month period ending June 30 is available, without charge, by calling 800.826.2333, or by visiting vaneck.com, or on the Securities and Exchange Commission’s website at http://www.sec.gov.
The Trust files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Trust’s Form N-Qs are available on the Commission’s website at http://www.sec.gov and may be reviewed and copied at the Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 202.942.8090. The Funds’ complete schedules of portfolio holdings are also available by calling 800.826.2333 or by visiting vaneck.com.
Investment Adviser: | Van Eck Associates Corporation | |
Distributor: | Van Eck Securities Corporation 666 Third Avenue, New York, NY 10017 vaneck.com |
|
Account Assistance: | 800.826.2333 | INDUSSAR |
SEMI-ANNUAL REPORT March 31, 2018 (unaudited) |
VANECK VECTORS® | |
Morningstar International Moat ETF | MOTI® |
Morningstar Wide Moat ETF | MOAT® |
NDR CMG Long/Flat Allocation ETF | LFEQTM |
Spin-Off ETF | SPUN® |
800.826.2333 | vaneck.com |
The information contained in the management discussion represents the opinions of VanEck Vectors ETF Trust and may differ from other persons. This information is not intended to be a forecast of future events, a guarantee of future results or investment advice. The information contained herein regarding each index has been provided by the relevant index provider. Also, unless otherwise specifically noted, any discussion of the Funds’ holdings and the Funds’ performance, and the views of VanEck Vectors ETF Trust are as of March 31, 2018, and are subject to change.
March 31, 2018 (unaudited)
Dear Shareholder:
We are pleased to present this semi-annual report for the six-month period ended March 31, 2018. Our three strategic equity exchange-traded funds (ETFs) of the VanEck Vectors® ETF Trust are now joined by the first of our guided allocation ETFs—VanEck Vectors NDR CMG Long/Flat Allocation ETF (NYSE Arca: LFEQ).
Managing Risk in the U.S. Equity Market
Building on our existing relationship with Ned Davis Research (NDR), the world-renowned provider of institutional quality research, we launched a new ETF with a guided allocation approach aimed at helping investors manage risk in the U.S. equity market.
Launched on October 4, 2017, LFEQ is designed to guide investors through volatile markets by opportunistically allocating between U.S. equity and cash. While many investors make an allocation to U.S. equity for the long-term growth potential, most probably do not realize that since 1928 the S&P 500® Index1 has spent approximately 70% of the time either in a bear market or recovering from one.2 This leaves the balance of time, only about 30%, available for the opportunity to generate new wealth.
Equity Markets Spent 70% of the Time in Market Decline and Recovery Periods 1/3/1928 - 3/31/2018
Source: Ned Davis Research, FactSet, S&P Dow Jones Indices. Based on price return, which excludes dividends. If calculated on a total return basis the figure would be 59%. Data as of 3/31/2018. Data plotted to logarithmic scale. For illustrative purposes only. Past performance is no guarantee of future results. See disclosures and index descriptions and definitions below.
For any investor, that is not a great deal of time spent growing new wealth. However, an investor’s experience will depend on where in the market cycle she or he starts investing. LFEQ provides investors with an ETF solution that offers a systematic approach that seeks both to participate in uptrends with a full allocation to equity and preserve capital by raising cash as market health weakens.
LFEQ seeks to track the Ned Davis Research CMG US Large Cap Long/Flat Index3 (NDRCMGLF). This is a rules-based index that follows a proprietary model developed by NDR and CMG Capital Management Group, Inc. The model produces trade signals that dictate the index’s equity allocation (100%, 80%, 40%, or 0%) and/or cash (U.S. T-bills) allocation.
1 |
VANECK VECTORS ETFs
(unaudited) (continued)
Second Partnership with Ned Davis Research
LFEQ is the second partnership between VanEck and Ned Davis Research, joining the VanEck® NDR Managed Allocation Fund (NDRMX), a tactical allocation mutual fund launched in May 2016. NDRMX follows a flexible NDR model allocating between U.S. and non-U.S. equity, U.S. debt, and U.S. cash and cash equivalents.
Access investment and market insights from VanEck’s investment professionals by subscribing to our blogs. To subscribe to the guided allocation updates, please contact us at 800.826.2333 or visit vaneck.com/subscription to register.
Thank you for participating in the VanEck Vectors ETF Trust. On the following pages, you will find the performance record of each of the funds for the six-month period ending March 31, 2018. You will also find their financial statements. We value your continuing confidence in us and look forward to helping you meet your investment goals in the future.
Jan F. van Eck
Trustee and President
VanEck Vectors ETF Trust
April 16, 2018
Represents the opinions of the investment adviser. Past performance is no guarantee of future results. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.
1 | S&P 500® Index consists of 500 widely held common stocks covering the leading industries in the U.S. economy. |
2 | Source: Ned Davis Research, S&P Dow Jones Indices. Based on price return, which excludes dividends. If calculated on a total return basis the figure would be 59%. Data as of 3/31/2018. Past performance is not indicative of future correlation or results. |
3 | Ned Davis Research CMG US Large Cap Long/Flat Index (NDRCMGLF) is a rules-based index that follows a proprietary model developed by Ned Davis Research, Inc. (“NDR”) in conjunction with CMG Capital Management Group, Inc. (“CMG”). The model produces daily trade signals to determine the Index’s equity allocation percentage (100%, 80%, 40%, or 0%). When allocated to a percentage of equities (long), that portion of the Index will comprise the S&P 500® Index. When allocated to a percentage of cash (flat), that portion of the Index will be allocated to the Solactive13-week U.S. T-bill Index. |
Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Certain indices may take into account withholding taxes. Investors cannot invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.
VanEck Vectors NDR CMG Long/Flat Allocation ETF (the “Fund”) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Ned Davis Research CMG US Large Cap Long/Flat Index (the “Index”).
The Fund is not sponsored, endorsed, sold or promoted by Ned Davis Research, Inc. or CMG Capital Management Group, Inc. NDR and CMG make no representation or warranty, express or implied, to the owners of the Fund or any member of the public regarding the advisability of investing in securities generally or in the Fund particularly or the ability of the Index to track the performance of equities market.
NEITHER NDR NOR CMG GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE INDEX OR ANY DATA INCLUDED THEREIN AND NEITHER NDR NOR CMG SHALL HAVE ANY LIABILITY WHATSOEVER FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. NDR AND CMG MAKE NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY LICENSEE, OWNERS OF THE FUND, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE INDEX OR ANY DATA INCLUDED THEREIN. NDR AND CMG MAKE NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL NDR OR CMG HAVE ANY LIABILITY, JOINTLY OR SEVERALLY, FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.
2 |
The S&P 500 Index is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Van Eck Associates Corporation. Copyright © 2018 S&P Dow Jones Indices LLC, a division of S&P Global, Inc., and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC. For more information on any of S&P Dow Jones Indices LLC’s indices please visit www.spdji.com. S&P® is a registered trademark of S&P Global and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC. Neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors make any representation or warranty, express or implied, as to the ability of any index to accurately represent the asset class or market sector that it purports to represent and neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors shall have any liability for any errors, omissions, or interruptions of any index or the data included therein.
3 |
VANECK VECTORS ETFs
(unaudited)
Management Discussion (unaudited)
All three VanEck Vectors Strategic Equity ETFs that traded for the full six-month period posted positive returns. Since VanEck Vectors NDR CMG Long/Flat Allocation ETF (LFEQ) was launched on October 4, 2017, it did not trade for the full reporting period.
Source: VanEck. Returns based on NAV. The performance data quoted represent past performance. Past performance is not a guarantee of future results. Performance information for the Funds reflects temporary waivers of expenses and/or fees. Had the Funds incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Funds will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than performance data quoted.
Morningstar International Moat
For the six-month period, VanEck Vectors Morningstar International Moat ETF (NYSE Arca: MOTI) returned 1.87%.* The primary drivers of the Fund’s performance were the financials and consumer discretionary sectors. The healthcare sector detracted most from performance followed by the energy and materials sectors.
Morningstar Wide Moat
VanEck Vectors Morningstar Wide Moat ETF (NYSE Arca: MOAT) returned 3.83%* for the six-month period. The primary driver of performance was the Fund’s exposure to the consumer discretionary sector. In addition, stocks in the information technology and financials sectors contributed solid positive returns. The health care sector was the single largest detractor from the Fund’s performance.
NDR CMG Long/Flat Allocation
Since inception on October 4, 2017, the Fund had traded for under six months by March 31, 2018. The Fund was up 4.11%.* The Fund’s allocation to equities changed twice during the period. In light of deteriorating market health, the Fund’s exposure to equites was reduced from 100% to 80% on November 22, 2017. However, on December 27, 2017, reacting quickly to increasing market health, the Fund’s allocation to equities returned to 100%, at which level it remained through the end of the period under review.
Spin-Off
VanEck Vectors Spin-Off ETF (NYSE Arca: SPUN) returned 2.79%.* During the six-month period, U.S. companies were by far the largest contributors to the Fund’s total returns. Ireland and the Cayman Islands were the largest detractors from performance. The three sectors contributing the most to performance were information technology, consumer discretionary, and materials. The energy, real estate, and utilities sectors were the only negative contributors to the Fund’s performance.
* | Returns based on NAV. |
4 |
VANECK VECTORS ETF TRUST
(unaudited)
Hypothetical $1,000 investment at beginning of period
As a shareholder of a Fund, you incur operating expenses, including management fees and other Fund expenses. This disclosure is intended to help you understand the ongoing costs (in dollars) of investing in your Fund and to compare these costs with the ongoing costs of investing in other mutual funds.
The disclosure is based on an investment of $1,000 invested at the beginning of the period and held for the entire period, October 1, 2017 to March 31, 2018.
Actual Expenses
The first line in the table below provides information about account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period.”
Hypothetical Example for Comparison Purposes
The second line in the table below provides information about hypothetical account values and hypothetical expenses based on the Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.
Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.
Beginning Account Value October 1, 2017 | Ending Account Value March 31, 2018 | Annualized Expense Ratio During Period | Expenses Paid During the Period* October 1, 2017 – March 31, 2018 | |||||||||||||
Morningstar International Moat ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,018.70 | 0.57 | % | $ | 2.87 | ||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,022.09 | 0.57 | % | $ | 2.87 | ||||||||
Morningstar Wide Moat ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,038.30 | 0.48 | % | $ | 2.44 | ||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,022.54 | 0.48 | % | $ | 2.42 | ||||||||
NDR CMG Long/Flat Allocation ETF*** | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,041.10 | 0.55 | % | $ | 2.74 | ||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,022.19 | 0.55 | % | $ | 2.77 | ||||||||
Spin-Off ETF | ||||||||||||||||
Actual | $ | 1,000.00 | $ | 1,027.90 | 0.55 | % | $ | 2.78 | ||||||||
Hypothetical** | $ | 1,000.00 | $ | 1,022.19 | 0.55 | % | $ | 2.77 |
* | Expenses are equal to the Fund’s annualized expense ratio (for the six months ended March 31, 2018) multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year divided by the number of days in the fiscal year (to reflect the one-half year period). |
** | Assumes annual return of 5% before expenses |
*** | Expenses are equal to the Fund’s annualized expense ratio (for the period from October 4, 2017 (commencement of operations) to March 31, 2018), multiplied by the average account value over the period, multiplied by the number of days since commencement of operations divided by the number of days in the fiscal year. |
5 |
VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 98.1% | ||||||||
Australia: 4.0% | ||||||||
144,899 | Brambles Ltd. # | $ | 1,116,855 | |||||
16,831 | Commonwealth Bank of Australia # | 939,995 | ||||||
114,328 | Crown Ltd. # | 1,121,361 | ||||||
39,866 | Westpac Banking Corp. # | 881,860 | ||||||
4,060,071 | ||||||||
Belgium: 1.0% | ||||||||
11,925 | KBC Group NV # | 1,037,910 | ||||||
Canada: 3.8% | ||||||||
11,375 | Canadian Imperial Bank of Commerce | 1,003,347 | ||||||
20,858 | National Bank of Canada | 981,058 | ||||||
21,027 | Nutrien Ltd. | 993,084 | ||||||
21,641 | TransCanada Corp. | 894,344 | ||||||
3,871,833 | ||||||||
China / Hong Kong: 16.3% | ||||||||
3,917,000 | Bank of China Ltd. # | 2,139,657 | ||||||
740,000 | Beijing Capital International Airport Co. Ltd. # | 999,409 | ||||||
368,500 | Beijing Enterprises Holdings Ltd. # | 1,940,516 | ||||||
600,000 | China Resources Gas Group Ltd. # | 2,098,158 | ||||||
247,000 | CK Asset Holdings Ltd. # | 2,084,411 | ||||||
155,200 | Hongkong Land Holdings Ltd. (USD) # | 1,072,279 | ||||||
2,442,000 | Industrial & Commercial Bank of China Ltd. # | 2,128,128 | ||||||
9,388 | SINA Corp. (USD) * | 978,887 | ||||||
127,000 | Sun Hung Kai Properties Ltd. # | 2,015,829 | ||||||
22,600 | Tencent Holdings Ltd. # | 1,213,135 | ||||||
16,670,409 | ||||||||
Denmark: 1.0% | ||||||||
26,282 | Danske Bank A/S # | 984,368 | ||||||
France: 2.8% | ||||||||
120,737 | Orange SA # | 2,051,269 | ||||||
10,487 | Sanofi # | 841,068 | ||||||
2,892,337 | ||||||||
Germany: 11.8% | ||||||||
16,297 | Bayer AG # | 1,836,327 | ||||||
19,714 | Bayerische Motoren Werke AG # | 2,143,242 | ||||||
42,649 | GEA Group AG # | 1,812,840 | ||||||
10,340 | HeidelbergCement AG # | 1,015,327 | ||||||
24,461 | KION Group AG # | 2,282,583 | ||||||
15,085 | Siemens AG # | 1,923,868 | ||||||
12,941 | Symrise AG # | 1,041,495 | ||||||
12,055,682 | ||||||||
India: 2.1% | ||||||||
68,780 | Infosys Ltd. # | 1,203,527 | ||||||
221,551 | Wipro Ltd. # | 959,736 | ||||||
2,163,263 | ||||||||
Italy: 2.0% | ||||||||
2,208,558 | Telecom Italia SpA * # | 2,095,991 | ||||||
Japan: 12.1% | ||||||||
11,400 | East Japan Railway Co. # | 1,066,381 | ||||||
4,300 | FANUC Corp. # | 1,107,191 | ||||||
11,700 | Hoshizaki Corp. # | 1,043,607 | ||||||
14,000 | Kao Corp. # | 1,051,573 | ||||||
37,200 | KDDI Corp. # | 958,560 |
Number | ||||||||
of Shares | Value | |||||||
Japan: (continued) | ||||||||
60,700 | Kubota Corp. # | $ | 1,070,549 | |||||
26,800 | LINE Corp. * # | 1,055,268 | ||||||
6,700 | Nidec Corp. # | 1,031,722 | ||||||
25,600 | Seven & i Holdings Co. Ltd. # | 1,097,075 | ||||||
24,200 | SoftBank Group Corp. # | 1,806,042 | ||||||
37,300 | Unicharm Corp. # | 1,076,421 | ||||||
12,364,389 | ||||||||
Luxembourg: 2.1% | ||||||||
31,816 | Millicom International Cellular SA (SEK) # | 2,170,818 | ||||||
Mexico: 5.0% | ||||||||
1,165,200 | America Movil, SAB de CV | 1,101,142 | ||||||
408,500 | Grupo Aeroportuario del Centro Norte SAB de CV | 1,983,922 | ||||||
211,700 | Grupo Aeroportuario del Pacifico SAB de CV | 2,083,309 | ||||||
5,168,373 | ||||||||
Netherlands: 2.9% | ||||||||
336,693 | Koninklijke KPN NV # | 1,011,940 | ||||||
51,623 | Koninklijke Philips NV # | 1,975,786 | ||||||
2,987,726 | ||||||||
New Zealand: 1.0% | ||||||||
256,666 | Contact Energy Ltd. # | 977,009 | ||||||
Russia: 1.0% | ||||||||
206,048 | Mobile TeleSystems PJSC # | 1,055,437 | ||||||
Singapore: 4.1% | ||||||||
751,800 | CapitaLand Ltd. # | 2,058,562 | ||||||
1,230,200 | Genting Singapore Plc # | 1,020,240 | ||||||
115,701 | Oversea-Chinese Banking Corp. Ltd. # | 1,139,640 | ||||||
4,218,442 | ||||||||
South Korea: 1.0% | ||||||||
4,829 | SK Telecom Co. Ltd. # | 1,047,104 | ||||||
Spain: 5.1% | ||||||||
127,415 | Banco Bilbao Vizcaya Argentaria SA # | 1,008,581 | ||||||
92,429 | Gas Natural SDG SA # | 2,205,027 | ||||||
36,729 | Grifols SA # | 1,040,791 | ||||||
97,302 | Telefonica SA # | 963,487 | ||||||
5,217,886 | ||||||||
Sweden: 3.6% | ||||||||
171,995 | Nordea Bank AB # | 1,834,847 | ||||||
75,306 | Svenska Handelsbanken AB # | 939,779 | ||||||
39,800 | Swedbank AB # | 891,650 | ||||||
3,666,276 | ||||||||
Switzerland: 2.0% | ||||||||
18,818 | LafargeHolcim Ltd. # | 1,029,403 | ||||||
4,338 | Roche Holding AG # | 993,462 | ||||||
2,022,865 | ||||||||
United Kingdom: 11.3% | ||||||||
237,360 | GKN Plc # | 1,538,314 | ||||||
2,223,901 | Lloyds Banking Group Plc # | 2,022,631 | ||||||
308,752 | Meggitt Plc # | 1,872,786 | ||||||
81,607 | Rolls-Royce Holdings Plc # | 997,595 | ||||||
95,920 | Smiths Group Plc # | 2,040,057 |
See Notes to Financial Statements
6 |
Number | ||||||||
of Shares | Value | |||||||
United Kingdom: (continued) | ||||||||
19,904 | Unilever Plc # | $ | 1,103,769 | |||||
717,684 | Vodafone Group Plc # | 1,963,326 | ||||||
11,538,478 | ||||||||
United States: 2.1% | ||||||||
478,200 | Samsonite International SA (HKD) # | 2,187,156 | ||||||
Total Common Stocks (Cost: $97,504,905) | 100,453,823 |
Number | ||||||||
of Shares | Value | |||||||
REAL ESTATE INVESTMENT TRUSTS: 2.1% (Cost: $2,101,101) | ||||||||
Singapore: 2.1% | ||||||||
1,373,200 | CapitaLand Mall Trust # | $ | 2,185,637 | |||||
Total Investments: 100.2% (Cost: $99,606,006) | 102,639,460 | |||||||
Liabilities in excess of other assets: (0.2)% | (217,704 | ) | ||||||
NET ASSETS: 100.0% | $ | 102,421,756 |
Definitions:
HKD | Hong Kong Dollar |
SEK | Swedish Krona |
USD | United States Dollar |
Footnotes:
* | Non-income producing |
# | Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $92,620,367 which represents 90.4% of net assets. |
Summary of Investments by Sector | % of Investments | Value | ||||||
Consumer Discretionary | 7.8 | % | $ | 8,010,313 | ||||
Consumer Staples | 4.2 | 4,328,838 | ||||||
Energy | 0.9 | 894,344 | ||||||
Financials | 17.5 | 17,933,451 | ||||||
Health Care | 6.5 | 6,687,434 | ||||||
Industrials | 23.7 | 24,373,190 | ||||||
Information Technology | 5.3 | 5,410,553 | ||||||
Materials | 4.0 | 4,079,309 | ||||||
Real Estate | 9.2 | 9,416,718 | ||||||
Telecommunication Services | 15.8 | 16,225,116 | ||||||
Utilities | 5.1 | 5,280,194 | ||||||
100.0 | % | $ | 102,639,460 |
See Notes to Financial Statements
7 |
VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices |
Level 2 Significant Observable Inputs |
Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks | |||||||||||||||||
Australia | $ | — | $ | 4,060,071 | $ | — | $ | 4,060,071 | |||||||||
Belgium | — | 1,037,910 | — | 1,037,910 | |||||||||||||
Canada | 3,871,833 | — | — | 3,871,833 | |||||||||||||
China / Hong Kong | 978,887 | 15,691,522 | — | 16,670,409 | |||||||||||||
Denmark | — | 984,368 | — | 984,368 | |||||||||||||
France | — | 2,892,337 | — | 2,892,337 | |||||||||||||
Germany | — | 12,055,682 | — | 12,055,682 | |||||||||||||
India | — | 2,163,263 | — | 2,163,263 | |||||||||||||
Italy | — | 2,095,991 | — | 2,095,991 | |||||||||||||
Japan | — | 12,364,389 | — | 12,364,389 | |||||||||||||
Luxembourg | — | 2,170,818 | — | 2,170,818 | |||||||||||||
Mexico | 5,168,373 | — | — | 5,168,373 | |||||||||||||
Netherlands | — | 2,987,726 | — | 2,987,726 | |||||||||||||
New Zealand | — | 977,009 | — | 977,009 | |||||||||||||
Russia | — | 1,055,437 | — | 1,055,437 | |||||||||||||
Singapore | — | 4,218,442 | — | 4,218,442 | |||||||||||||
South Korea | — | 1,047,104 | — | 1,047,104 | |||||||||||||
Spain | — | 5,217,886 | — | 5,217,886 | |||||||||||||
Sweden | — | 3,666,276 | — | 3,666,276 | |||||||||||||
Switzerland | — | 2,022,865 | — | 2,022,865 | |||||||||||||
United Kingdom | — | 11,538,478 | — | 11,538,478 | |||||||||||||
United States | — | 2,187,156 | — | 2,187,156 | |||||||||||||
Real Estate Investment Trusts* | — | 2,185,637 | — | 2,185,637 | |||||||||||||
Total | $ | 10,019,093 | $ | 92,620,367 | $ | — | $ | 102,639,460 |
* See Schedule of Investments for geographic sector breakouts.
During the period ended March 31, 2018, transfers of securities from Level 2 to Level 1 were $3,019,905. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.
See Notes to Financial Statements
8 |
VANECK VECTORS MORNINGSTAR WIDE MOAT ETF
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number | ||||||||
of Shares | Value | |||||||
COMMON STOCKS: 99.7% | ||||||||
Banks: 2.4% | ||||||||
614,289 | Wells Fargo & Co. | $ | 32,194,886 | |||||
Capital Goods: 6.0% | ||||||||
261,493 | Emerson Electric Co. | 17,859,972 | ||||||
2,063,085 | General Electric Co. | 27,810,386 | ||||||
59,371 | TransDigm Group, Inc. † | 18,223,335 | ||||||
139,711 | United Technologies Corp. | 17,578,438 | ||||||
81,472,131 | ||||||||
Commercial & Professional Services: 2.2% | ||||||||
512,501 | Stericycle, Inc. * | 29,996,684 | ||||||
Consumer Durables & Apparel: 2.8% | ||||||||
307,744 | NIKE, Inc. | 20,446,511 | ||||||
238,757 | VF Corp. | 17,696,669 | ||||||
38,143,180 | ||||||||
Consumer Services: 3.9% | ||||||||
117,126 | McDonald’s Corp. | 18,316,164 | ||||||
616,477 | Starbucks Corp. | 35,687,854 | ||||||
54,004,018 | ||||||||
Diversified Financials: 3.6% | ||||||||
175,044 | American Express Co. | 16,328,104 | ||||||
321,986 | Charles Schwab Corp. | 16,814,109 | ||||||
454,025 | Franklin Resources, Inc. | 15,745,587 | ||||||
48,887,800 | ||||||||
Energy: 1.3% | ||||||||
330,207 | Cheniere Energy, Inc. * | 17,649,564 | ||||||
Food & Staples Retailing: 2.3% | ||||||||
507,765 | CVS Caremark Corp. | 31,588,061 | ||||||
Food, Beverage & Tobacco: 7.6% | ||||||||
414,293 | Campbell Soup Co. † | 17,943,030 | ||||||
349,544 | General Mills, Inc. | 15,750,453 | ||||||
178,692 | Hershey Co. | 17,683,360 | ||||||
829,655 | Mondelez International, Inc. | 34,621,503 | ||||||
162,489 | PepsiCo, Inc. | 17,735,674 | ||||||
103,734,020 | ||||||||
Health Care Equipment & Services: 16.1% | ||||||||
400,968 | AmerisourceBergen Corp. | 34,567,451 | ||||||
523,268 | Cardinal Health, Inc. | 32,798,438 | ||||||
518,963 | Express Scripts Holding Co. * | 35,849,964 | ||||||
237,874 | McKesson Corp. | 33,509,310 | ||||||
424,878 | Medtronic Plc | 34,083,713 | ||||||
269,144 | Veeva Systems, Inc. * | 19,652,895 | ||||||
281,073 | Zimmer Biomet Holdings, Inc. | 30,648,200 | ||||||
221,109,971 | ||||||||
Household & Personal Products: 1.3% | ||||||||
225,464 | The Procter and Gamble Co. | 17,874,786 | ||||||
Materials: 4.8% | ||||||||
539,963 | Compass Minerals International, Inc. † | 32,559,769 | ||||||
283,082 | Monsanto Co. | 33,032,839 | ||||||
65,592,608 |
Number | ||||||||
of Shares | Value | |||||||
Media: 8.2% | ||||||||
494,124 | Comcast Corp. | $ | 16,884,217 | |||||
305,512 | John Wiley & Sons, Inc. | 19,461,114 | ||||||
1,127,584 | Twenty-First Century Fox, Inc. | 41,371,057 | ||||||
344,689 | Walt Disney Co. | 34,620,563 | ||||||
112,336,951 | ||||||||
Pharmaceuticals, Biotechnology: 17.2% | ||||||||
208,866 | Allergan Plc | 35,150,059 | ||||||
191,598 | Amgen, Inc. | 32,663,627 | ||||||
116,404 | Biogen Idec, Inc. * | 31,873,743 | ||||||
267,381 | Bristol-Myers Squibb Co. | 16,911,848 | ||||||
432,956 | Eli Lilly & Co. | 33,497,806 | ||||||
220,196 | Gilead Sciences, Inc. | 16,600,576 | ||||||
628,866 | Merck and Co., Inc. | 34,254,331 | ||||||
970,841 | Pfizer, Inc. | 34,455,147 | ||||||
235,407,137 | ||||||||
Retailing: 7.7% | ||||||||
26,539 | Amazon.com, Inc. * | 38,410,956 | ||||||
802,674 | L Brands, Inc. | 30,670,174 | ||||||
417,904 | Lowe’s Cos, Inc. | 36,671,076 | ||||||
105,752,206 | ||||||||
Semiconductor: 2.4% | ||||||||
364,170 | Microchip Technology, Inc. | 33,270,571 | ||||||
Software & Services: 8.7% | ||||||||
194,559 | Guidewire Software, Inc. * | 15,726,204 | ||||||
190,151 | Microsoft Corp. | 17,355,082 | ||||||
303,950 | Salesforce.com, Inc. * | 35,349,385 | ||||||
1,729,786 | The Western Union Co. | 33,263,785 | ||||||
150,367 | Visa, Inc. | 17,986,901 | ||||||
119,681,357 | ||||||||
Utilities: 1.2% | ||||||||
244,857 | Dominion Resources, Inc. | 16,510,708 | ||||||
Total Common Stocks (Cost: $1,346,915,369) | 1,365,206,639 | |||||||
Principal Amount | ||||||||
SHORT-TERM INVESTMENTS HELD AS | ||||||||
COLLATERAL FOR SECURITIES ON LOAN: 2.3% | ||||||||
Repurchase Agreements: 2.3% | ||||||||
$ | 7,558,818 | Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $7,560,347; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $7,709,994 including accrued interest) | 7,558,818 | |||||
1,589,409 | Repurchase agreement dated 3/29/18 with Credit Agricole CIB, 1.75%, due 4/2/18, proceeds $1,589,718; (collateralized by various U.S. government and agency obligations, 1.50% to 1.63%, due 12/31/18 to 10/15/20, valued at $1,621,197 including accrued interest) | 1,589,409 |
See Notes to Financial Statements
9 |
VANECK VECTORS MORNINGSTAR WIDE MOAT ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
Principal | ||||||||
Amount | Value | |||||||
Repurchase Agreements: (continued) | ||||||||
$ | 7,558,818 | Repurchase agreement dated 3/29/18 with Daiwa Capital Markets America, Inc., 1.81%, due 4/2/18, proceeds $7,560,338; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 4/30/18 to 12/1/51, valued at $7,709,995 including accrued interest) | $ | 7,558,818 | ||||
7,558,818 | Repurchase agreement dated 3/29/18 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.81%, due 4/2/18, proceeds $7,560,338; (collateralized by various U.S. government and agency obligations, 0.00% to 4.50%, due 12/1/26 to 4/1/48, valued at $7,709,994 including accrued interest) | 7,558,818 |
Principal | ||||||||
Amount | Value | |||||||
Repurchase Agreements: (continued) | ||||||||
$ | 7,558,818 | Repurchase agreement dated 3/29/18 with Nomura Securities International, Inc., 1.82%, due 4/2/18, proceeds $7,560,347; (collateralized by various U.S. government and agency obligations, 0.00% to 7.50%, due 4/2/18 to 2/20/68, valued at $7,709,994 including accrued interest) | $ | 7,558,818 | ||||
Total Short-Term Investments Held as
Collateral for Securities on Loan (Cost: $31,824,681) |
31,824,681 | |||||||
Total Investments: 102.0% (Cost: $1,378,740,050) |
1,397,031,320 | |||||||
Liabilities in excess of other assets: (2.0)% | (27,903,130 | ) | ||||||
NET ASSETS: 100.0% | $ | 1,369,128,190 |
Footnotes:
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $31,807,762. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Consumer Discretionary | 22.7 | % | $ | 310,236,355 | ||||
Consumer Staples | 11.2 | 153,196,867 | ||||||
Energy | 1.3 | 17,649,564 | ||||||
Financials | 5.9 | 81,082,686 | ||||||
Health Care | 33.5 | 456,517,108 | ||||||
Industrials | 8.2 | 111,468,815 | ||||||
Information Technology | 11.2 | 152,951,928 | ||||||
Materials | 4.8 | 65,592,608 | ||||||
Utilities | 1.2 | 16,510,708 | ||||||
100.0 | % | $ | 1,365,206,639 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices |
Level 2 Significant Observable Inputs |
Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks* | $ | 1,365,206,639 | $ | — | $ | — | $ | 1,365,206,639 | |||||||||
Repurchase Agreements | — | 31,824,681 | — | 31,824,681 | |||||||||||||
Total | $ | 1,365,206,639 | $ | 31,824,681 | $ | — | $ | 1,397,031,320 |
* See Schedule of Investments for industry sector breakouts.
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
10 |
VANECK VECTORS NDR CMG LONG/FLAT ALLOCATION ETF
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number | ||||||||
of Shares | Value | |||||||
EXCHANGE TRADED FUND: 99.6% (Cost: $35,705,043) | ||||||||
144,280 | Vanguard S&P 500 ETF | $ | 34,927,302 | |||||
MONEY MARKET FUND: 0.5% (Cost: $160,096) | ||||||||
160,096 | Dreyfus Government Cash Management Fund – Institutional Shares | 160,096 | ||||||
Total Investments: 100.1% (Cost: $35,865,139) |
35,087,398 | |||||||
Liabilities in excess of other assets: (0.1)% | (35,188 | ) | ||||||
NET ASSETS: 100.0% | $ | 35,052,210 |
Summary of Investments by Sector | % of Investments | Value | ||||||
Exchange Traded Fund | 99.5 | % | $ | 34,927,302 | ||||
Money Market Fund | 0.5 | 160,096 | ||||||
100.0 | % | $ | 35,087,398 |
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices |
Level 2 Significant Observable Inputs |
Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Exchange Traded Fund | $ | 34,927,302 | $ | — | $ | — | $ | 34,927,302 | |||||||||
Money Market Fund | 160,096 | — | — | 160,096 | |||||||||||||
Total | $ | 35,087,398 | $ | — | $ | — | $ | 35,087,398 |
There were no transfers between levels during the period ended March 31, 2018.
See Notes to Financial Statements
11 |
SCHEDULE OF INVESTMENTS
March 31, 2018 (unaudited)
Number of Shares | Value | |||||||
COMMON STOCKS: 85.8% | ||||||||
Australia: 2.2% | ||||||||
20,395 | Orora Ltd. # | $ | 52,038 | |||||
20,033 | South32 Ltd. # | 50,281 | ||||||
102,319 | ||||||||
Cayman Islands: 1.0% | ||||||||
1,887 | Theravance Biopharma, Inc. (USD) * † | 45,760 | ||||||
China / Hong Kong: 4.1% | ||||||||
145,000 | China Overseas Property Holdings Ltd. # | 45,814 | ||||||
6,000 | CK Asset Holdings Ltd. # | 50,633 | ||||||
854,000 | Global Brands Group Holding Ltd. * # | 48,319 | ||||||
8,000 | Wharf Real Estate Investment Co. Ltd. * # | 52,290 | ||||||
197,056 | ||||||||
Denmark: 1.1% | ||||||||
1,083 | Nilfisk Holding A/S * # | 51,075 | ||||||
Finland: 2.1% | ||||||||
6,688 | Caverion Corp. * † # | 50,616 | ||||||
2,574 | Valmet OYJ # | 51,578 | ||||||
102,194 | ||||||||
France: 1.1% | ||||||||
504 | Fnac Darty SA * # | 53,911 | ||||||
Germany: 2.1% | ||||||||
2,776 | METRO AG # | 49,084 | ||||||
685 | OSRAM Licht AG # | 50,383 | ||||||
99,467 | ||||||||
Ireland: 1.1% | ||||||||
617 | Allegion Plc (USD) | 52,624 | ||||||
Italy: 1.1% | ||||||||
8,976 | Italgas SpA # | 53,609 | ||||||
Norway: 1.1% | ||||||||
9,427 | Aker Solutions ASA * # Reg S | 50,245 | ||||||
Singapore: 1.1% | ||||||||
34,900 | Frasers Centrepoint Ltd. # | 53,319 | ||||||
Sweden: 3.3% | ||||||||
17,464 | Arjo AB * # | 50,890 | ||||||
3,878 | Bonava AB # | 53,110 | ||||||
5,097 | Svenska Cellulosa AB # | 54,307 | ||||||
158,307 | ||||||||
Switzerland: 1.1% | ||||||||
2,116 | Idorsia Ltd. * # | 50,819 | ||||||
United Kingdom: 3.4% | ||||||||
1,096 | Delphi Technologies PLC (USD) | 52,224 | ||||||
32,904 | Gocompare.Com Group Plc | 51,697 | ||||||
9,058 | Indivior Plc * # | 51,771 | ||||||
478 | Micro Focus International Plc (ADR) | 6,711 | ||||||
162,403 | ||||||||
United States: 59.9% | ||||||||
871 | Adient Plc | 52,051 | ||||||
1,480 | AdvanSix, Inc. * | 51,474 | ||||||
1,162 | Alcoa Corp. * | 52,244 | ||||||
1,434 | Associated Capital Group, Inc. † | 53,703 | ||||||
996 | Brighthouse Financial, Inc. * | 51,194 | ||||||
76 | Cable One, Inc. | 52,220 | ||||||
3,262 | California Resources Corp. * † | 55,943 | ||||||
1,750 | Cars.com, Inc. * | 49,578 |
Number of Shares | Value | |||||||
United States: (continued) | ||||||||
800 | CDK Global, Inc. | $ | 50,672 | |||||
1,073 | Chemours Co. | 52,266 | ||||||
13,278 | Civeo Corp. * | 50,058 | ||||||
2,694 | Conduent, Inc. * † | 50,216 | ||||||
1,774 | CONSOL Energy, Inc. * | 51,393 | ||||||
1,139 | CSW Industrials, Inc. * | 51,312 | ||||||
2,994 | Donnelley Financial Solutions, Inc. * | 51,407 | ||||||
1,002 | Energizer Holdings, Inc. † | 59,699 | ||||||
2,361 | Enova International, Inc. * | 52,060 | ||||||
1,881 | Exterran Corp. * | 50,223 | ||||||
680 | Fortive Corp. | 52,714 | ||||||
5,218 | Gannett Co., Inc. † | 52,076 | ||||||
1,775 | GCP Applied Technologies, Inc. * | 51,564 | ||||||
1,110 | Halyard Health, Inc. * | 51,149 | ||||||
770 | Herc Holdings, Inc. * † | 50,012 | ||||||
2,848 | Hewlett Packard Enterprise Co. | 49,954 | ||||||
1,198 | Hilton Grand Vacations, Inc. * | 51,538 | ||||||
695 | Ingevity Corp. * | 51,215 | ||||||
2,912 | International Seaways, Inc. * | 51,251 | ||||||
1,006 | Keysight Technologies, Inc. * | 52,704 | ||||||
751 | KLX, Inc. * | 53,366 | ||||||
4,027 | Knowles Corp. * † | 50,700 | ||||||
956 | Lamb Weston Holdings, Inc. | 55,658 | ||||||
2,456 | Lands’ End, Inc. * | 57,348 | ||||||
612 | Liberty Broadband Corp. * | 51,898 | ||||||
2,870 | LSC Communications, Inc. | 50,081 | ||||||
756 | Lumentum Holdings, Inc. * † | 48,233 | ||||||
214 | Madison Square Garden Co. * | 52,601 | ||||||
3,647 | Mallinckrodt Plc * † | 52,809 | ||||||
742 | Murphy USA, Inc. * † | 54,018 | ||||||
3,977 | Navient Corp. | 52,178 | ||||||
2,987 | New Media Investment Group, Inc. † | 51,197 | ||||||
3,207 | News Corp. | 50,671 | ||||||
4,801 | NOW, Inc. * † | 49,066 | ||||||
799 | ONE Gas, Inc. | 52,750 | ||||||
664 | PayPal Holdings, Inc. * | 50,378 | ||||||
1,727 | Pinnacle Entertainment, Inc. * † | 52,069 | ||||||
1,065 | PJT Partners, Inc. † | 53,356 | ||||||
2,616 | Rayonier Advanced Materials, Inc. † | 56,166 | ||||||
689 | Science Applications International Corp. | 54,293 | ||||||
1,007 | SPX FLOW, Inc. * | 49,534 | ||||||
3,294 | TimkenSteel Corp. * † | 50,036 | ||||||
658 | TopBuild Corp. * | 50,350 | ||||||
1,440 | Varex Imaging Corp. * | 51,523 | ||||||
1,368 | Versum Materials, Inc. | 51,478 | ||||||
3,182 | Vista Outdoor, Inc. * | 51,930 | ||||||
2,653 | Welbilt, Inc. * | 51,601 | ||||||
2,857,178 | ||||||||
Total Common Stocks (Cost: $3,545,438) | 4,090,286 | |||||||
REAL ESTATE INVESTMENT TRUSTS: 14.4% | ||||||||
United States: 14.4% | ||||||||
3,781 | CareTrust REIT, Inc. | 50,665 | ||||||
9,236 | Colony NorthStar, Inc. † | 51,906 | ||||||
2,329 | Four Corners Property Trust, Inc. | 53,777 | ||||||
1,575 | Gaming and Leisure Properties, Inc. | 52,715 | ||||||
3,114 | New Residential Investment Corp. | 51,225 | ||||||
6,639 | New Senior Investment Group, Inc. | 54,307 |
See Notes to Financial Statements
12 |
Number of Shares | Value | |||||||
United States: (continued) | ||||||||
4,125 | NorthStar Realty Europe Corp. | $ | 53,707 | |||||
1,979 | Park Hotels and Resorts, Inc. | 53,473 | ||||||
2,724 | Quality Care Properties, Inc. * | 52,927 | ||||||
3,192 | Uniti Group, Inc. * † | 51,870 | ||||||
2,517 | Urban Edge Properties | 53,738 | ||||||
8,091 | Washington Prime Group, Inc. † | 53,967 | ||||||
2,654 | Xenia Hotels and Resorts, Inc. | 52,337 | ||||||
Total Real Estate Investment Trusts (Cost: $751,465) | 686,614 | |||||||
MONEY MARKET FUND: 0.4% (Cost: $21,887) | ||||||||
21,887 | Dreyfus Government Cash Management Fund – Institutional Shares | 21,887 | ||||||
Total Investments Before Collateral for Securities Loaned: 100.6% (Cost: $4,318,790) | 4,798,787 |
Principal Amount | Value | |||||||
SHORT-TERM INVESTMENT HELD AS | ||||||||
COLLATERAL FOR SECURITIES ON LOAN: 19.1% (Cost: $909,458) | ||||||||
Repurchase Agreement: 19.1% | ||||||||
$ | 909,458 | Repurchase agreement dated 3/29/18 with Citigroup Global Markets, Inc., 1.82%, due 4/2/18, proceeds $909,642; (collateralized by various U.S. government and agency obligations, 0.00% to 10.00%, due 5/15/18 to 10/20/67, valued at $927,647 including accrued interest) | $ | 909,458 | ||||
Total Investments: 119.7% (Cost: $5,228,248) | 5,708,245 | |||||||
Liabilities in excess of other assets: (19.7)% | (938,984 | ) | ||||||
NET ASSETS: 100.0% | $ | 4,769,261 |
Definitions:
ADR | American Depositary Receipt |
USD | United States Dollar |
Footnotes:
* | Non-income producing |
† | Security fully or partially on loan. Total market value of securities on loan is $904,903. |
# | Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $1,024,092 which represents 21.5% of net assets. |
Reg S | Security was purchased pursuant to Regulation S under the Securities Act of 1933, which exempts from registration securities offered and sold outside of the United States. Such a security cannot be sold in the United States without either an effective registration statement filed pursuant to the Securities Act of 1933, or pursuant to an exemption from registration. |
Summary of Investments by Sector Excluding Collateral for Securities Loaned | % of Investments | Value | ||||||
Consumer Discretionary | 18.5 | % | $ | 887,531 | ||||
Consumer Staples | 3.4 | 164,441 | ||||||
Energy | 5.4 | 259,055 | ||||||
Financials | 7.6 | 365,123 | ||||||
Health Care | 7.4 | 354,721 | ||||||
Industrials | 15.9 | 763,598 | ||||||
Information Technology | 10.8 | 517,036 | ||||||
Materials | 10.9 | 521,591 | ||||||
Real Estate | 17.4 | 837,445 | ||||||
Utilities | 2.2 | 106,359 | ||||||
Money Market Fund | 0.5 | 21,887 | ||||||
100.0 | % | $ | 4,798,787 |
See Notes to Financial Statements
13 |
VANECK VECTORS SPIN-OFF ETF
SCHEDULE OF INVESTMENTS
(unaudited) (continued)
The summary of inputs used to value the Fund’s investments as of March 31, 2018 is as follows:
Level 1 Quoted Prices | Level 2 Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Value | ||||||||||||||
Common Stocks | |||||||||||||||||
Australia | $ | — | $ | 102,319 | $ | — | $ | 102,319 | |||||||||
Cayman Islands | 45,760 | — | — | 45,760 | |||||||||||||
China / Hong Kong | — | 197,056 | — | 197,056 | |||||||||||||
Denmark | — | 51,075 | — | 51,075 | |||||||||||||
Finland | — | 102,194 | — | 102,194 | |||||||||||||
France | — | 53,911 | — | 53,911 | |||||||||||||
Germany | — | 99,467 | — | 99,467 | |||||||||||||
Ireland | 52,624 | — | — | 52,624 | |||||||||||||
Italy | — | 53,609 | — | 53,609 | |||||||||||||
Norway | — | 50,245 | — | 50,245 | |||||||||||||
Singapore | — | 53,319 | — | 53,319 | |||||||||||||
Sweden | — | 158,307 | — | 158,307 | |||||||||||||
Switzerland | — | 50,819 | — | 50,819 | |||||||||||||
United Kingdom | 110,632 | 51,771 | — | 162,403 | |||||||||||||
United States | 2,857,178 | — | — | 2,857,178 | |||||||||||||
Real Estate Investment Trusts* | 686,614 | — | — | 686,614 | |||||||||||||
Money Market Fund | 21,887 | — | — | 21,887 | |||||||||||||
Repurchase Agreement | — | 909,458 | — | 909,458 | |||||||||||||
Total | $ | 3,774,695 | $ | 1,933,550 | $ | — | $ | 5,708,245 |
* See Schedule of Investments for geographic sector breakouts.
During the period ended March 31, 2018, transfers of securities from Level 1 to Level 2 were $329,139, transfers of securities from Level 2 to Level 1 were $56,353. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.
See Notes to Financial Statements
14 |
[This Page Intentionally Left Blank.]
15 |
VANECK VECTORS ETF TRUST
STATEMENTS OF ASSETS AND LIABILITIES
March 31, 2018 (unaudited)
See Notes to Financial Statements
16 |
VANECK VECTORS ETF TRUST
For the Six Months Ended March 31, 2018 (unaudited)
(a) | For the period October 4, 2017 (commencement of operations) through March 31, 2018. |
See Notes to Financial Statements
17 |
VANECK VECTORS ETF TRUST
STATEMENTS OF CHANGES IN NET ASSETS
See Notes to Financial Statements
18 |
VANECK VECTORS ETF TRUST
STATEMENTS OF CHANGES IN NET ASSETS
* | Commencement of operations |
See Notes to Financial Statements
19 |
VANECK VECTORS ETF TRUST
For a share outstanding throughout each period:
(a) | Commencement of operations |
(b) | Calculated based upon average shares outstanding |
(c) | Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares. |
(d) | Not Annualized |
(e) | Annualized |
(f) | Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions. |
See Notes to Financial Statements
20 |
VANECK VECTORS ETF TRUST
FINANCIAL HIGHLIGHTS
For a share outstanding throughout each period:
(a) | Commencement of operations |
(b) | Calculated based upon average shares outstanding |
(c) | Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares. |
(d) | Not Annualized |
(e) | Annualized |
(f) | Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions. |
(g) | The ratios presented do not reflect the Fund’s proportionate share of income and expenses from the Fund’s investment in underlying funds. |
(h) | The amount shown for a share outstanding does not correspond with the aggregate net gain (loss) on investments for the period due to the timing and repurchase of shares in relation to fluctuating market values of the investments of the Fund. |
See Notes to Financial Statements
21 |
VANECK VECTORS ETF TRUST
March 31, 2018 (unaudited)
Note 1—Fund Organization—VanEck Vectors ETF Trust (the “Trust”) is registered under the Investment Company Act of 1940, as amended, as an open-end management investment company. The Trust was incorporated in Delaware as a statutory trust on March 15, 2001. The Trust operates as a series fund, and as of March 31, 2018, offers fifty-six investment portfolios, each of which represents a separate series of the Trust.
These financial statements relate only to the following investment portfolios: Morningstar International Moat ETF, Morningstar Wide Moat ETF, NDR CMG Long/Flat Allocation ETF, and Spin-Off ETF (formerly known as Global Spin-Off ETF), (each a “Fund” and, together, the “Funds”). Each Fund was created to provide investors with the opportunity to purchase a security representing a proportionate undivided interest in a portfolio of securities consisting of substantially all of the common stocks in substantially the same weighting, in an index sponsored, licensed or managed by Morningstar, Inc., Ned Davis Research, Inc. or Horizon Kinetics, LLC.
The Funds’ respective indices are presented below:
Fund | Index | |
Morningstar International Moat ETF | Morningstar® Global ex-US Moat Focus IndexSM(1) | |
Morningstar Wide Moat ETF | Morningstar® Wide Moat Focus IndexSM(1) | |
NDR CMG Long/Flat Allocation ETF | Ned Davis Research CMG US Large Cap Long/Flat Index(2) | |
Spin-Off ETF | Horizon Kinetics Global Spin-Off Index(3) |
(1) | Published by Morningstar, Inc. |
(2) | Published by Ned Davis Research, Inc. |
(3) | Published by Horizon Kinetics, LLC |
Note 2—Significant Accounting Policies—The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.
The Funds are investment companies and are following accounting and reporting requirements of Accounting Standards Codification (“ASC”) 946 Financial Services—Investment Companies.
The following is a summary of significant accounting policies followed by the Funds.
A. | Security Valuation—The Funds value their investments in securities and other assets and liabilities at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Securities traded on national exchanges or traded on the NASDAQ National Market System are valued at the last sales price as reported at the close of each business day. Securities traded on the NASDAQ Stock Market are valued at the NASDAQ official closing price. Over-the-counter securities not included in the NASDAQ National Market System and listed securities for which no sale was reported are valued at the mean of the bid and ask prices. To the extent these securities are actively traded they are categorized as Level 1 in the fair value hierarchy (described below). Certain foreign securities, whose values may be affected by market direction or events occurring before the Funds’ pricing time (4:00 p.m. Eastern Standard Time) but after the last close of the securities’ primary market, are fair valued using a pricing service and are categorized as Level 2 in the fair value hierarchy. The pricing service, using methods approved by the Board of Trustees, considers the correlation of the trading patterns of the foreign security to intraday trading in the U.S. markets, based on indices of domestic securities and other appropriate indicators such as prices of relevant ADR’s and futures contracts. The Funds may also fair value securities in other situations, such as, when a particular foreign market is closed but the Fund is open. Short-term obligations with sixty days or less to maturity are valued at amortized cost, which with accrued interest approximates fair value. Money market fund investments are valued at net asset value and are considered to be Level 1 in the fair value hierarchy. The Pricing Committee of the Van Eck Associate Corporation (the “Adviser”) provides oversight of the Funds’ valuation policies and procedures, which are approved by the Funds’ Board of Trustees. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities dealers, and other market sources to determine fair value. The Pricing Committee convenes regularly to review the fair value of financial instruments or other assets. If market quotations for a security or other asset are not readily available, or if the Adviser believes it does not otherwise reflect the fair value of a security or asset, the security or asset will be fair valued by the Pricing Committee in accordance with the Funds’ valuation policies and procedures. The Pricing Committee employs various methods for calibrating |
22 |
the valuation approaches utilized to determine fair value, including a regular review of key inputs and assumptions, periodic comparisons to valuations provided by other independent pricing services, transactional back-testing and disposition analysis. | |
Certain factors such as economic conditions, political events, market trends, the nature of and duration of any restrictions on disposition, trading in similar securities of the issuer or comparable issuers and other security specific information are used to determine the fair value of these securities. Depending on the relative significance of valuation inputs, these securities may be classified either as Level 2 or Level 3 in the fair value hierarchy. The price which the Funds may realize upon sale of an investment may differ materially from the value presented in the Schedules of Investments. | |
The Funds utilize various methods to measure the fair value of their investments on a recurring basis, which includes a hierarchy that prioritizes inputs to valuation methods used to measure fair value. The fair value hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The transfers between levels of the fair value hierarchy assume the financial instruments where transferred at the beginning of the reporting period. The three levels of the fair value hierarchy are described below: | |
Level 1 — Quoted prices in active markets for identical securities. | |
Level 2 — Significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). | |
Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). | |
A summary of the inputs, the levels used to value the Funds’ investments, and transfers between levels are located in the Schedules of Investments. Additionally, tables that reconcile the valuation of the Funds’ Level 3 investments and that present additional information about valuation methodologies and unobservable inputs, if applicable, are located in the Schedules of Investments. | |
B. | Federal Income Taxes—It is each Fund’s policy to comply with the provisions of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Therefore, no federal income tax provision is required. |
C. | Dividends and Distributions to Shareholders—Dividends to shareholders from net investment income and distributions from net realized capital gains, if any, are declared and paid annually by each Fund. Income dividends and capital gain distributions are determined in accordance with U.S. income tax regulations, which may differ from such amounts determined in accordance with GAAP. |
D. | Currency Translation—Assets and liabilities denominated in foreign currencies and commitments under foreign currency contracts are translated into U.S. dollars at the closing prices of such currencies each business day as quoted by one or more sources. Purchases and sales of investments are translated at the exchange rates prevailing when such investments are acquired or sold. Foreign denominated income and expenses are translated at the exchange rates prevailing when accrued. The portion of realized and unrealized gains and losses on investments that result from fluctuations in foreign currency exchange rates is not separately disclosed in the financial statements. Recognized gains or losses attributable to foreign currency fluctuations on foreign currency denominated assets, other than investments, and liabilities are recorded as net realized gain (loss) on foreign currency transactions and foreign denominated assets and liabilities in the Statements of Operations. |
E. | Restricted Securities—The Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities, if any, is included at the end of each Fund’s Schedule of Investments. |
23 |
VANECK VECTORS ETF TRUST
NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)
F. | Repurchase Agreements—The Funds may enter into repurchase agreements with financial institutions, deemed to be creditworthy by the Adviser, to generate income from their excess cash balances and to invest securities lending cash collateral. A repurchase agreement is an agreement under which a Fund acquires securities from a seller, subject to resale to the seller at an agreed upon price and date. A Fund, through its custodian/securities lending agent, takes possession of securities collateralizing the repurchase agreement. Pursuant to the terms of the repurchase agreement, such securities must have an aggregate market value greater than or equal to the terms of the repurchase price plus accrued interest at all times. If the value of the underlying securities falls below the value of the repurchase price plus accrued interest, the Funds will require the seller to deposit additional collateral by the next business day. If the request for additional collateral is not met, or the seller defaults on its repurchase obligation, the Funds maintain their right to sell the underlying securities at market value and may claim any resulting loss against the seller. Repurchase agreements held as of March 31, 2018 are reflected in the Schedules of Investments. |
G. | Offsetting Assets and Liabilities—In the ordinary course of business, the Funds enter into transactions subject to enforceable master netting or other similar agreements. Generally, the right of setoff in those agreements allows the Funds to set off any exposure to a specific counterparty with any collateral received or delivered to that counterparty based on the terms of the agreements. The Funds may pledge or receive cash and/or securities as collateral for derivative instruments, securities lending and repurchase agreements. For financial reporting purposes, the Funds present securities lending and repurchase agreement assets and liabilities on a gross basis in the Statements of Assets and Liabilities. Collateral held at March 31, 2018 is presented in the Schedules of Investments. Refer to related disclosures in Note 2G (Repurchase Agreements) and Note 9 (Securities Lending). |
H. | Other—Security transactions are accounted for on trade date. Realized gains and losses are determined based on the specific identification method. Dividend income is recorded on the ex-dividend date except that certain dividends from foreign securities are recognized upon notification of the ex-dividend date. Interest income, including amortization of premiums and discounts, is accrued as earned. The Funds may record distributions received in excess of income from certain underlying investments as a reduction of cost of investments and/or as an increase in capital gains. Such amounts are based on estimates if actual amounts are not available, and actual amounts of income, realized gains and return of capital may differ from estimated amounts. |
In the normal course of business, the Funds enter into contracts that contain a variety of general indemnifications. The Funds’ maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Funds that have not yet occurred. However, the Adviser believes the risk of loss under these arrangements to be remote. | |
Note 3—Investment Management and Other Agreements—The Adviser is the investment adviser to the Funds. The Adviser receives a management fee, calculated daily and payable monthly based on an annual rate of each Fund’s average daily net assets. The Adviser has agreed, until at least February 1, 2019, to waive management fees and assume expenses to prevent each Fund’s total annual operating expenses (excluding acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses) from exceeding expense limitations listed in the table below.
The current management fee rate, expense limitations and the amounts waived/assumed by the Adviser for the period ended March 31, 2018, are as follows:
Management | Expense | |||||||
Fund | Fee Rate | Limitations | ||||||
Morningstar International Moat ETF | 0.50 | % | 0.56 | % | ||||
Morningstar Wide Moat ETF | 0.45 | 0.49 | ||||||
NDR CMG Long/Flat Allocation ETF | 0.50 | 0.55 | ||||||
Spin-Off ETF | 0.50 | 0.55 |
Refer to Statements of Operations for the amounts waived/assumed by the Adviser.
In addition, Van Eck Securities Corporation, an affiliate of the Adviser, acts as the Funds’ distributor (“the Distributor”). Certain officers and a Trustee of the Trust are officers, directors or stockholders of the Adviser and Distributor.
24 |
Note 4—Investments—For the period ended March 31, 2018, the cost of purchases and proceeds from sales of investments other than U.S. government obligations and short-term obligations (excluding in-kind transactions described in Note 6) were as follows:
Cost of Investments | Proceeds from | |||||||
Fund | Purchased | Investments Sold | ||||||
Morningstar International Moat ETF | $ | 46,931,543 | $ | 49,463,193 | ||||
Morningstar Wide Moat ETF | 333,849,947 | 340,697,462 | ||||||
NDR CMG Long/Flat Allocation ETF | 1,011,350 | 1,045,799 | ||||||
Spin-Off ETF | 1,171,925 | 1,204,489 |
Note 5—Income Taxes—As of March 31, 2018, for Federal income tax purposes, the identified cost, gross unrealized appreciation, gross unrealized depreciation, and net unrealized appreciation(depreciation) of investments were as follows:
Net Unrealized | ||||||||||||||||
Gross Unrealized | Gross Unrealized | Appreciation | ||||||||||||||
Fund | Cost of Investments | Appreciation | Depreciation | (Depreciation) | ||||||||||||
Morningstar International Moat ETF | $ | 100,361,854 | $ | 5,542,331 | $ | (3,264,725 | ) | $ | 2,277,606 | |||||||
Morningstar Wide Moat ETF | 1,378,827,110 | 95,133,703 | (76,929,493 | ) | 18,204,210 | |||||||||||
NDR CMG Long/Flat Allocation ETF | 35,865,139 | — | (777,741 | ) | (777,741 | ) | ||||||||||
Spin-Off ETF | 5,234,939 | 825,693 | (352,387 | ) | 473,306 |
The tax character of dividends paid to shareholders during the year ended September 30, 2017 was as follows:
2017 Dividends | ||||
Fund | Ordinary Income | |||
Morningstar International Moat ETF | $ | 407,000 | ||
Morningstar Wide Moat ETF | 9,710,400 | |||
Spin-Off ETF | 48,600 |
The tax character of current year distributions will be determined at the end of the current year.
At September 30, 2017, the tax character of current year distributions will be determined at the end of the current fiscal year. The Funds had capital loss carryforwards available to offset future capital gains, as follows:
Post-Effective- | Post-Effective- | |||||||||||
No Expiration | No Expiration | |||||||||||
Short-Term | Long-Term | |||||||||||
Fund | Capital Losses | Capital Losses | Total | |||||||||
Morningstar Wide Moat ETF | $ | (102,440,499 | ) | $ | (32,265,944 | ) | $ | (134,706,443 | ) | |||
Spin-Off ETF | (58,333 | ) | — | (58,333 | ) |
The Funds recognize the tax benefits of uncertain tax positions only where the position is “more-likely-than-not” to be sustained assuming examination by applicable tax authorities. Management has analyzed the Funds’ tax positions, and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on return filings for all open tax years. The Funds do not have exposure for additional years that might still be open in certain foreign jurisdictions. Therefore, no provision for income tax is required in the Funds’ financial statements. However, certain Funds are subject to foreign taxes on the appreciation in value of certain investments. The Funds provide for such taxes on both realized and unrealized appreciation.
The Funds recognize interest and penalties, if any, related to uncertain tax positions as income tax expense in the Statements of Operations. During the period ended March 31, 2018, the Funds did not incur any interest or penalties.
Note 6—Capital Share Transactions—As of March 31, 2018, there were an unlimited number of capital shares of beneficial interest authorized by the Trust with no par value. Fund shares are not individually redeemable and are issued and redeemed at their net asset value per share only through certain authorized broker-dealers (“Authorized Participants”) in blocks of shares (“Creation Units”), consisting of 50,000 shares, or multiples thereof.
The consideration for the purchase or redemption of Creation Units of the Funds generally consists of the in-kind contribution or distribution of securities constituting the Funds’ underlying index (“Deposit Securities”) plus a balancing cash component to equate the transaction to the net asset value per share of the Fund on the transaction date. Cash may also be substituted in an amount equivalent to the value of certain Deposit Securities, generally as a result of
25 |
VANECK VECTORS ETF TRUST
NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)
market circumstances, or when the securities are not available in sufficient quantity for delivery or are not eligible for trading by the Authorized Participant. The Funds may issue Creation Units in advance of receipt of Deposit Securities subject to various conditions, including a requirement to maintain on deposit at the Custodian for the benefit of the Funds, collateral consisting of cash in the form of U.S. dollars at least equal to 115% of the daily marked to market value of the missing Deposit Securities.
Authorized Participants purchasing and redeeming Creation Units may pay transaction fees directly to The Bank of New York Mellon. In addition, the Funds may impose certain variable fees for creations and redemptions with respect to transactions in Creation Units for cash, or on transactions effected outside the clearing process, which are treated as increases in capital. These variable fees, if any, are reflected in share transactions in the Statements of Changes in Net Assets.
For the period ended March 31, 2018, the Funds had in-kind contributions and redemptions as follows:
Fund | In-Kind Contributions | In-Kind Redemptions | ||||||
Morningstar International Moat ETF | $ | 33,798,551 | $ | 10,160,351 | ||||
Morningstar Wide Moat ETF | 341,731,226 | 288,821,782 | ||||||
NDR CMG Long/Flat Allocation ETF | 38,223,925 | 2,624,973 | ||||||
Spin-Off ETF | — | 1,201,058 |
The in-kind contributions and in-kind redemptions in this table represent the accumulation of each Fund’s daily net shareholder transactions including rebalancing activity, while the Statements of Changes in Net Assets reflect shareholder transactions including any cash component of the transactions.
Note 7—Concentration of Risk—The investment objective of each Fund is to seek investment results that correspond generally to the price and yield performance, before fees and expenses, of its underlying index, as indicated in the name of each Fund. The Adviser uses a “passive” or index approach to achieve each Fund’s investment objective by investing in a portfolio of securities that generally replicates the Funds’ index. Each of the Fund is classified as a non-diversified fund under the 1940 Act. Non-diversified funds generally hold securities of fewer issuers than diversified funds and may be more susceptible to the risks associated with these particular issuers, or to a single economic, political or regulatory occurrence affecting these issuers. The Funds may purchase securities on foreign exchanges. Securities of foreign issuers involve special risks and considerations not typically associated with investing in U.S. issuers. These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.
NDR CMG Long/Flat Allocation ETF may invest in shares of other funds, including ETFs that track the S&P 500 Index. As a result, the Fund will indirectly be exposed to the risks of an investment in the underlying funds. Shares of other funds have many of the same risks as direct investments in common stocks or bonds. In addition, the market value of the Fund’s shares is expected to rise and fall as the value of the underlying index or bond rises and falls. The market value of such funds’ shares may differ from the net asset value of the particular fund.
Spin-Off ETF may invest in companies that have been spun-off from a parent company for a number of reasons, including but not limited to low growth prospects, high capital requirements or an unfavorable capitalization structure. Investments in spun-off companies are subject to the risk that any of these characteristics will adversely affect the value of investments in the spun-off companies. There can be no assurance that a spun-off company will be financially independent or profitable, especially where the company represented a non-core or non-competitive business line of the parent company at the time of the spin-off.
Spin-Off ETF may invest directly in real estate investment trusts (“REITs”) and is exposed to the risk of owning real estate directly, as well as to risks that relate specifically to the way in which REITs are organized and operated. REITs generally invest directly in real estate, in mortgages or in some combination of the two. The Fund indirectly bears management expenses along with the direct expenses of the Fund. Individual REITs may own a limited number of properties and may concentrate in a particular region or property type. REITs may also be subject to heavy cash flow dependency, default by borrowers and self-liquidation.
26 |
In March 2017, the United Kingdom triggered Article 50, and is now scheduled to leave the European Union (“EU”) by the end of March 2019. Significant uncertainty exists on how the withdrawal will take place, the terms of the withdrawal and the effects such withdrawal will have on the EU and the United Kingdom. This may further impact the value of the Euro and the British pound sterling, and has caused volatility and uncertainty in European and global markets
As a result of events involving Ukraine and the Russian Federation, the United States and the European Union have imposed sanctions on certain Russian individuals and companies. These sanctions do not currently impact the Funds. Additional economic sanctions may be imposed or other actions may be taken that may adversely affect the value and liquidity of the Russian-related issuers held by the Funds.
A more complete description of risks is included in each Fund’s Prospectus and Statement of Additional Information.
Note 8—Trustee Deferred Compensation Plan—The Trust has a Deferred Compensation Plan (the “Plan”) for Trustees under which the Trustees can elect to defer receipt of their trustee fees until retirement, disability or termination from the Board of Trustees. The fees otherwise payable to the participating Trustees are deemed invested in shares of the Funds as directed by the Trustees.
The expense for the Plan is included in “Trustees’ fees and expenses” in the Statements of Operations. The liability for the Plan is shown as “Deferred Trustee fees” in the Statements of Assets and Liabilities.
Note 9—Securities Lending—To generate additional income, each of the Funds may lend its securities pursuant to a securities lending agreement with The Bank of New York Mellon, the securities lending agent and also the Funds’ custodian. Each Fund may lend up to 33% of its investments requiring that the loan be continuously collateralized by cash, U.S. government or U.S. government agency securities, shares of an investment trust or mutual fund, or any combination of cash and such securities at all times equal to at least 102% (105% for foreign securities) of the market value plus accrued interest on the securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled on the next business day. During the term of the loan, the Funds will continue to receive any dividends, interest or amounts equivalent thereto on the securities loaned, while receiving a fee from the borrower and/or earning interest on the investment of the cash collateral. Such fees and interest are shared with the securities lending agent under the terms of the securities lending agreement. The Funds may pay reasonable finders’, administrative and custodial fees in connection with a loan of its securities. Securities lending income is disclosed as such in the Statements of Operations. The collateral for securities loaned is recognized in the Schedules of Investments and the Statements of Assets and Liabilities. The cash collateral is maintained on the Funds’ behalf by the lending agent and is invested in repurchase agreements collateralized by obligations of the U.S. Treasury and/or Government Agencies. Loans are subject to termination at the option of the borrower or the Funds. Upon termination of the loan, the borrower will return to the lender securities identical to the securities loaned. The Funds bear the risk of delay in recovery of, or even loss of rights in, the securities loaned should the borrower of the securities fail financially. The value of loaned securities and related collateral outstanding at March 31, 2018 are presented on a gross basis in the Schedules of Investments and Statements of Assets and Liabilities.
The following table presents repurchase agreements held as collateral by type of security on loan as of March 31, 2018:
Gross Amount of Recognized | ||||
Liabilities for Securities Loaned | ||||
in the Statements of Assets | ||||
and Liabilities* | ||||
Fund | Equity Securities | |||
Morningstar Wide Moat ETF | $ | 31,824,681 | ||
Spin-Off ETF | 909,458 |
* | Remaining contractual maturity of the agreements: overnight and continuous |
27 |
VANECK VECTORS ETF TRUST
NOTES TO FINANCIAL STATEMENTS
(unaudited) (continued)
Note 10—Bank Line of Credit—The Funds may participate in a $200 million committed credit facility (the “Facility”) to be utilized for temporary financing until the settlement of sales or purchases of portfolio securities, the repurchase or redemption of shares of the Funds and other temporary or emergency purposes. The Funds have agreed to pay commitment fees, pro rata, based on the unused but available balance. Interest is charged to the Funds at rates based on prevailing market rates in effect at the time of borrowings. During the year ended March 31, 2018, the following Funds borrowed under this Facility:
Outstanding Loan | ||||||||||||||||
Days | Average Daily | Average | Balance as of | |||||||||||||
Fund | Outstanding | Loan Balance | Interest Rate | March 31, 2018 | ||||||||||||
Morningstar International Moat ETF | 87 | $ | 369,954 | 2.73 | % | $ | 635,888 | |||||||||
Morningstar Wide Moat ETF | 145 | 1,942,211 | 2.68 | — |
Note 11—Custodian Fees—The Funds have entered into an expense offset agreement with the custodian wherein they receive a credit toward the reduction of custodian fees whenever there are uninvested cash balances. The Funds could have invested their cash balances elsewhere if they had not agreed to a reduction in fees under the expense offset agreement with the custodian. For the period ended March 31, 2018, there were offsets to custodian fees and these amounts are reflected in custody expense in the Statements of Operations.
Note 12—Subsequent Event Review—The Funds have evaluated subsequent events and transactions for potential recognition or disclosure through the date the financial statements were issued.
28 |
VANECK VECTORS ETF TRUST
APPROVAL OF INVESTMENT MANAGEMENT AGREEMENT
March 31, 2018 (unaudited)
At a meeting held on September 7, 2017 (the “Meeting”), the Board of Trustees (the “Board”) of VanEck Vectors® ETF Trust (the “Trust”), including all of the Trustees that are not interested persons of the Trust (the “Independent Trustees”), considered and approved an investment management agreement between the Trust and Van Eck Associates Corporation (the “Adviser”) (the “Investment Management Agreement”) with respect to the VanEck Vectors Real Asset Allocation ETF (the “Fund”).
The Board’s approval of the Investment Management Agreement was based on a comprehensive consideration of all of the information available to the Trustees and was not the result of any single factor. Some of the factors that figured particularly in the Trustees’ deliberations and how the Trustees considered those factors are described below, although individual Trustees may have evaluated the information presented differently, giving different weights to various factors.
In advance of the Meeting, the Trustees received materials from the Adviser, including expense information for other funds. The Adviser provided the Trustees with information regarding, among other things, the various aspects of the Fund’s proposed investment program, fee arrangements and service provider arrangements. The Independent Trustees’ consideration of the Investment Management Agreement was based, in part, on their review of information obtained through discussions with the Adviser at the Meeting regarding the management of the Fund, information obtained at other meetings of the Trustees and/or based on their review of the materials provided by the Adviser, including the background and experience of the portfolio managers and others proposed to be involved in the management and administration of the Fund. The Trustees considered the terms and scope of services that the Adviser would provide under the Investment Management Agreement, including the Adviser’s commitment to waive certain fees and/or pay expenses of the Fund to the extent necessary to prevent the operating expenses of the Fund from exceeding agreed upon limits for a period of at least one year following the effective date of their respective registration statements.
The Trustees considered the benefits, other than the fees under the Investment Management Agreement, that the Adviser would receive from serving as adviser to the Fund. The Trustees did not consider historical information about the cost of the services provided by the Adviser or the profitability of the Fund to the Adviser because the Fund had not yet commenced operations. In addition, because the Fund had not yet commenced operations, the Trustees could not consider the historical performance or the quality of services previously provided to the Fund by the Adviser, although they concluded that the nature, quality, and extent of the services to be provided by the Adviser were appropriate based on the Trustees’ knowledge of the Adviser and its personnel and the operations of the other series of the Trust.
The Independent Trustees were advised by and met in executive session with their independent counsel at the Meeting as part of their consideration of the Investment Management Agreement.
In voting to approve the Investment Management Agreement, the Trustees, including the Independent Trustees, concluded that the terms of the Investment Management Agreement are reasonable and fair in light of the services to be performed, expenses to be incurred and such other matters as the Trustees considered relevant in the exercise of their reasonable judgment. The Trustees further concluded that the Investment Management Agreement is in the best interest of the Fund and the Fund’s shareholders.
29 |
This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by a VanEck Vectors ETF Trust (the “Trust”) Prospectus, which includes more complete information. An investor should consider the investment objective, risks, and charges and expenses of the Funds carefully before investing. The prospectus contains this and other information about the investment company. Please read the prospectus carefully before investing.
Additional information about the Trust’s Board of Trustees/Officers and a description of the policies and procedures the Trust uses to determine how to vote proxies relating to portfolio securities are provided in the Statement of Additional Information. The Statement of Additional Information and information regarding how the Trust voted proxies relating to portfolio securities during the most recent twelve month period ending June 30 is available, without charge, by calling 800.826.2333, or by visiting vaneck.com, or on the Securities and Exchange Commission’s website at http://www.sec.gov.
The Trust files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Trust’s Form N-Qs are available on the Commission’s website at http://www.sec.gov and may be reviewed and copied at the Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 202.942.8090. The Funds’ complete schedules of portfolio holdings are also available by calling 800.826.2333 or by visiting vaneck.com.
Investment Adviser: | Van Eck Associates Corporation | |
Distributor: | Van Eck Securities Corporation | |
666 Third Avenue, New York, NY 10017 | ||
vaneck.com | ||
Account Assistance: | 800.826.2333 | STRATSAR |
Item 2. CODE OF ETHICS. Not applicable. Item 3. AUDIT COMMITTEE FINANCIAL EXPERT. Not applicable. Item 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES. Not applicable. Item 5. AUDIT COMMITTEE OF LISTED REGISTRANTS. Not applicable. Item 6. SCHEDULE OF INVESTMENTS. Information included in Item 1. Item 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES. Not applicable. Item 8. PORTFOLIO MANAGER OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES. Not applicable. Item 9. PURCHASE OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS. Not applicable. Item 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. Not applicable. Item 11. CONTROLS AND PROCEDURES. (a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act") (17 CFR 270.30a-3(c)) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)). (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d)) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. Item 12. DISCLOSURE OF SECURITIES LENDING ACTIVITIES FOR CLOSED-END MANAGEMENT COMPANIES. Not applicable. Item 13. EXHIBITS. (a)(1) Not applicable. (a)(2) A separate certification for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)) is attached as Exhibit 99.CERT. (b) Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 is furnished as Exhibit 99.906CERT.
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. (Registrant) VANECK VECTORS ETF TRUST By (Signature and Title) /s/ John J. Crimmins, Treasurer & Chief Financial Officer --------------------------------------------------------- Date June 8, 2018 --------------- Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. By (Signature and Title) /s/ Jan F. van Eck, Chief Executive Officer -------------------------------------------- Date June 8, 2018 --------------- By (Signature and Title) /s/ John J. Crimmins, Treasurer & Chief Financial Officer ----------------------------------------------------------- Date June 8, 2018 ---------------